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CHAPTER 1: Introduction 
1.1 Epidemiology of Heart Failure 
Heart failure (HF) is a major public health problem, with a prevalence of more than 5.8 
million in the United States and more than 23 million worldwide. In 1997, HF was singled 
out as an “emerging epidemic”1.  
In the American Heart Association (AHA)/American College of Cardiology guidelines2, HF 
is defined as “a complex clinical syndrome that can result from any structural or functional 
cardiac disorder that impairs the ability of the ventricle to fill or eject blood.” The guidelines 
underscore that “it is largely a clinical diagnosis that is based on a careful history and 
physical examination.” As HF is a syndrome and not a disease, its diagnosis relies on a 
clinical examination and can be challenging. To assess the burden of HF in populations and 
study its epidemiology, standardized criteria that can be used on a large scale for its 
ascertainment from medical records are needed. 
Several criteria have been proposed to diagnose HF,  including the Framingham criteria3, 
the Boston criteria4, the Gothenburg criteria5, and the European Society of Cardiology 
criteria6. 
Using standardized criteria, the incidence of HF in an earlier study from Framingham was 
between 1.4 and 2.3 per 1000/y among persons aged 29 to 79 years. However, the size of 
the cohort inherently limits the power to analyze secular trends in this report. 
Croft et al7, comparing the rates of initial hospitalization for HF using Medicare hospital 
claims in 1986 and 1993, reported an increase in the initial hospitalization for HF, while 
acknowledging limitations related to the lack of validation and possible incomplete 
ascertainment of incidence. Data from the Henry Ford Health system8, a managed care 
organization, indicated that the prevalence of HF was increasing over time but did not detect 
any secular change in incidence or mortality. In the Framingham Heart Study9 and the 
Olmsted County Study10 which include outpatient HF, the incidence of HF remained stable 
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over time or even declined in women. It should be noted that, although the interpretation 
and informal comparison of trends across studies is appropriate, as adjustment approaches 
differ, the absolute numbers couldn’t be compared. Importantly, the trends noted among the 
elderly are different and data from the Kaiser Permanente system comparing the incidence 
of HF in 1970–1974 and 1990–1994 among persons aged ≥65 years indicated that the age-
adjusted incidence increased by 14% over time and was greater for older persons and for 
men11. The Framingham and Olmsted County studies also reported trends toward increasing 
HF incidence among older persons, which are concerning given the aging of the population. 
In the Rotterdam Heart Study, the lifetime risk of HF at the age of 55 years was 33% for 
men and 29% for women12. These numbers are commensurate with the data from the United 
States.  
In summary, the overall prevalence of HF ranges from 1% to 12% based on available data 
from the United States and Europe. The incidence of HF varies across studies largely 
reflecting differences in ascertainment and adjustment approaches. These methodological 
differences, however, do not affect the interpretation of secular trends in incidence where 
the focus is on the evolution over time. Temporal trends are congruent across studies and 
quite informative for the investigation of the HF epidemic because they indicate that the 
incidence of HF is stable or perhaps even decreasing over time. Available data indicate that 
lifetime risks are high regardless of sex, race, and geography, underscoring the importance 
of population-wide efforts to contain the burden of HF. 
 
1.2 Mortality of HF 
After the diagnosis of HF, survival estimates are 50% and 10% at 5 and 10 years, 
respectively13, and left ventricular dysfunction is associated with an increase in the risk of 
sudden death14. 
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In the Henry Ford Health system, which includes outpatient encounters, the median survival 
was 4.2 years without any discernible improvement over time. Similarly, among >2 million 
elderly Medicare beneficiaries, early- and long-term mortality remained quite high (115% at 
30 days and 37% at 1 year)15. Data from Framingham and Olmsted County underscored the 
persistently high mortality of HF in these populations, despite improvements over time; 
indeed, after age adjustment, estimated 5-year mortality rates were 59% in men and 45% in 
women during the time period 1990–1999 in Framingham and 50% in men and 46% in 
women during the time period 1996–2000 in Olmsted County. Improvements in survival 
were noted more specifically within an elderly population as shown by data from the Kaiser 
Permanente system. Indeed, during the two decades between the mid-1970s and mid-1990s 
after adjustment for age and comorbidities, survival after the diagnosis of HF improved by 
33% in men and 24% in women. Importantly, in the Kaiser Permanente study, improvement 
in survival was primarily associated with β-blocker treatment. Data from Ontario16 and 
Scotland17 also support the observation that although survival after HF diagnosis remains 
quite poor, improvements have been detected since the late 1990s. Altogether, these trends 
in mortality coincide temporally with major changes in the treatment of HF and thus suggest 
that HF treatment is effective in the community but that much progress remains to be 
accomplished. The causes of death in HF can be challenging to ascertain. In the community, 
cardiovascular deaths are less frequent among subjects with preserved EF. Indeed, in 
Olmsted County, MN, among 1063 persons with HF, the leading cause of death in subjects 
with preserved EF was non-cardiovascular (49%) versus coronary disease (43%) for 
subjects with reduced EF. The proportion of cardiovascular deaths decreased from 69% in 
1979–1984 to 40% in 1997–2002 (P=0.007) among subjects with preserved EF contrasting 
with a modest change among those with reduced EF (77%–64%, P=0.08)18. The shift in the 
distribution of the causes of death toward less cardiovascular causes is congruent with the 
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major burden of comorbid conditions in HF and is of crucial importance for the 
management of HF and the interpretation of its outcomes. 
In summary, survival after the diagnosis of HF remains quite poor but has improved 
substantially over time. The results are consistent across studies and, combined with the 
aforementioned trends in incidence, indicated that the epidemic of HF is an epidemic of 
hospitalizations among survivors who now live longer with the disease. 
 
1.3 Hospitalizations in HF 
HF is characterized by periodic exacerbations that require treatment intensification most 
often in the hospital and is the single most frequent cause of hospitalization in persons aged 
≥65 years. Nearly one million hospitalizations for HF occur each year with rates of 
hospitalization continuing to rise. This trend, coupled with the forecasting of a major 
increase in the prevalence of HF by the AHA19, underscores the persisting severity of the 
burden that HF creates on healthcare systems and the need for continued surveillance of HF 
trends to delineate strategies for management. A subsequent analysis of CMS data indicates 
that after an initial hospitalization, 25% of HF patients are readmitted within 30 days with 
35% of readmissions also attributed to HF20. Data from the Veteran’s Affairs Health Care 
System also support the notion that as mortality was decreasing, readmission rates have in 
fact increased over time21. Taken collectively, these important reports suggest that that 
threshold for admitting patients with HF to the hospital might be evolving. However, once 
patients have been hospitalized with HF, their risk of readmission is not decreasing over 
time but they will be readmitted rather infrequently because of HF. National Hospital 
Discharge Survey data from 1979 to 2004 indicate that although HF was the first-listed 
diagnosis for 30% to 35% of these hospitalizations, the proportion with respiratory diseases 
and non-cardiovascular, non-respiratory diseases as the first-listed diagnoses increased over 
time22. In the community of Olmsted County, among incident HF cases diagnosed between 
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1987 and 2006, hospitalizations were common after HF diagnosis, with 83% of the patients 
hospitalized at least once but the reason for hospitalization was HF in only 17% of 
hospitalizations, whereas 62% were attributed to non-cardiovascular causes23. Using the 
Nationwide Inpatient Sample, Blecker et al reported on trends in HF hospitalizations 
between 2001 and 2009. Primary HF hospitalizations declined, but hospitalizations with a 
secondary diagnosis of HF remained stable24.  
In summary, these data underscore the major role of comorbidity in HF25 and that, to reduce 
the burden of hospitalizations in HF, strategies must consider both cardiac disease and 
noncardiac conditions. While initial hospitalizations are seemingly decreasing, readmissions 
after an initial hospitalization are not declining such that, with the increased survival of 
patients living with HF, the overall burden of hospitalizations in HF remains large. 
 
1.4 Treatment of HF 
Heart Transplantation 
Heart transplantation is an accepted treatment for end-stage HF26. Although controlled trials 
have never been conducted, there is consensus that transplantation—provided that proper 
selection criteria are applied—significantly increases survival, exercise capacity, quality of 
life, and return to work compared with conventional treatment. Apart from the shortage of 
donor hearts, the main challenges in transplantation are the consequences of the limited 
effectiveness and complications of immunosuppressive therapy in the long term (i.e. 
antibody-mediated rejection, infection, hypertension, renal failure, malignancy, and 
coronary artery vasculopathy). 
 
Mechanical Circulatory Support 
For selected patients with end-stage HF, transplantation remains the gold-standard 
treatment, with good long-term survival. However, because of the increasing numbers of 
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patients with end-stage HF, limited organ donation, and technological advances, MCS with 
an LV assist device (LVAD) or bi-ventricular assist device (BiVAD) is increasingly seen as 
an alternative for some of these individuals. Initially MCS was used as a short-term BTT 
treatment but is now being used long-term, as so-called ‘destination therapy (DT)’, in 
patients not eligible for transplantation. Ventricular assist devices may ultimately become a 
more general alternative to transplantation, as current 2- to 3-year survival rates in carefully 
selected patients receiving the latest continuous flow devices are much better than with 
medical therapy only27. Patients receiving these devices also have a post-transplant survival 
rate similar to those not requiring bridging. However, despite technological improvements, 
bleeding, thromboembolism (both of which can cause stroke), infection, and device failure 
remain significant problems; these issues, plus the high cost of devices and implantation, 
have limited their wider use. It is recommended that such devices are only implanted and 
managed at tertiary heart failure centers with appropriately trained, specialist HF physicians 
and surgeons. Ideally these centers should also undertake transplantation. 
 
Coronary Revascularization in HF 
Surgical (and percutaneous) coronary revascularization is indicated for the relief of angina 
pectoris in patients with HF, and surgical coronary revascularization is indicated for 
‘prognostic’ reasons in other patients with severe CAD, particularly those with three-vessel 
disease or left-main stenosis. 
The benefit–risk balance for CABG in patients without angina/ischemia or without viable 
myocardium remains uncertain. Patients with >10% of dysfunctional but viable LV 
myocardium may be more likely to benefit from myocardial revascularization (and those 
with ≤10% less likely to benefit) although this approach to patient selection for 
revascularization is unproven. Several non-invasive techniques can be used to assess 
myocardial viability. Nuclear imaging has a high sensitivity, whereas techniques evaluating 
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contractile reserve have lower sensitivity but higher specificity. CMR is excellent for 
assessing the transmural extent of scar, but is not better at detecting viability or predicting 
recovery of wall motion. 
The choice between percutaneous coronary intervention and CABG should be made by the 
Heart Team, including a HF specialist, and be based on the extent of CAD, expected 
completeness of revascularization, associated valvular disease, and the presence of co-
morbidities. 
 
Surgical Ventricular Reconstruction 
LV remodeling is a complex process that may occur in several clinical conditions, including 
MI, leading to chamber dilatation, altered configuration and increased wall stress. LV 
remodeling usually begins within the first few hours after an MI and results from the fibrotic 
repair of the necrotic area with scar formation, elongation and thinning of the infarcted 
zone. LV volumes increase, a response that is sometimes considered adaptive, associated 
with stroke volume augmentation, in an effort to maintain a normal cardiac output as the 
ejection fraction declines28. However, beyond this early stage, the remodeling process is 
driven predominantly by eccentric hypertrophy of the non-infarcted remote regions, 
resulting in increased wall mass, chamber enlargement and geometric distortion29. 
Surgical LV reconstruction (LVR) has been introduced as an optional therapeutic strategy 
aimed at reducing LV volumes through the exclusion of the scar tissue, thereby reducing the 
ventricle to a more physiological volume, reshaping the distorted chamber and improving 
cardiac function through a reduction of LV wall stress in accordance with the principle of 
Laplace’s law. Since LV wall stress is directly proportional to LV internal radius and 
pressure and inversely proportional to wall thickness, any intervention to optimize this 
relationship would be beneficial either in terms of improving wall compliance and reducing 
filling pressure or, as wall stress is a crucial determinant of afterload, in terms of enhancing 
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contractile performance of the LV by increasing the extent and velocity of systolic fiber 
shortening30.  
Furthermore, LVR of failing ventricles is usually combined with myocardial 
revascularization with the aim of treating the underlying coronary artery disease. Finally, 
although the matter of functional chronic ischemic mitral regurgitation (MR), in terms of 
whether, when and how it should be corrected, is still considerably controversial, it should 
be pointed out that LVR offers either the possibility of repairing the mitral valve through the 
LV opening or the potential of improving mitral functioning by reducing LV volumes, 
papillary muscles distance and hence rebuilding a more normal geometry31. Although a 
large amount of reports drawn on various data sets from registries and mainly observational 
studies have shown that LVR is effective and relatively safe with a favorable 5-year 
outcome32, the results from the STICH trial have called into question the additional benefit 
of the surgical LVR. Beyond the debate that will probably continue for a long time, the Task 
Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and 
the European Association for Cardio-Thoracic Surgery (EACTS) recognized the merit of 
LVR, which has been included as a surgical option combined with CABG in selected HF 
patients with a scar in the LAD territory and a baseline LVESVI ≥60 ml/ m2 (Class of 
Recommendation IIb; level of evidence B)33. 
 
1.5 Rationale for a translational approach for HF therapy 
Ischemic heart disease continues to be the single most frequent cause of death worldwide. 
Although acute and long-term mortality following acute myocardial infarction (AMI) has 
declined thanks to therapeutic advances, 12% of patients still die within 6 months of AMI. 
Overall medical, surgical and transplantation therapy are largely ineffective to effectively 
cure the growing number of patients affected by HF.  In the last decade HF cardiologists and 
physicians were more and more involved in developing a translational approach to HF, in 
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order to better understand the cellular and molecular basis of the disease to finally develop 
new therapeutic strategy. 
The discovery in 2001 that stem cells have the potential to regenerate the heart in infarcted 
mice was rapidly translated into the clinic34. Cell-based products (CBPs) have been 
evaluated in patients with AMI, refractory angina and chronic heart failure (CHF) to assess 
whether these therapies are safe and efficacious in improving heart function and preventing 
the development of end-stage heart failure.  
However meta-analyses of clinical data show contradictory results; furthermore the clinical 
development of cell-based therapies in patients with CHF is more challenging than in AMI. 
Indeed patients with CHF have a different pathophysiology and clinical presentation with 
extensive remodeling, collagen accumulation, and profound ultra-structural changes. 
One interesting approach, developed in our laboratory was to investigate the role of the 
Hypoxia Inducible Factor (HIF) in protecting skeletal muscle cells and cardiomyocytes from 
hypoxia or ischemia. Indeed there are several mechanisms that activate and regulate HIF 
expression. In this view, one possible therapeutic approach could be the activation of HIF in 
order to increase the cardiac response to hypoxic stress. 
 
1.6 Molecular Mechanisms in response to cellular hypoxia: the Hypoxia 
Inducible Factor (HIF) 
Hypoxia determines important consequences at a functional level that can ultimately lead to 
cellular death and tissue irreversible damage. Under hypoxic condition, cells activate a 
complex of protective genetic pathways, that are yet to be completely understood, aiming to 
enhance cellular survival despite oxygen deprivation. The key factor of cellular response to 
hypoxia is the Hypoxia Inducible Factor 1α (HIF-1α), a transcriptional factor that regulates 
the cellular response to reduced oxygen availability35.  In fact, it has been demonstrated that 
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HIF-1 is expressed ubiquitously in almost all mammalian cells. This basic helix-loop-helix 
(bHLH)-Per-AHR-ARNT-Sim (PAS) transcription factor is a key element in sensing 
changes of cellular oxygen tension. HIF-1 is a heterodimer composed of an oxygen-
sensitive α subunit and constitutively expressed β subunit (ie arylhydrocarbon receptor 
nuclear translocator -ARNT)36. More explicitly, oxygen levels can affect the protein 
stability, subcellular localization and transcriptional activity of the HIF α subunits (HIF-1α, 
HIF-2α and HIF-3α), whereas the ARNT subunit is constitutively expressed in the nucleus 
and its activity is not affected by hypoxia37. As illustrated in Figure 1, under normoxic 
condition, the α subunit of HIF-1 is rapidly ubiquitinated and degraded proteosomally by 
hydroxylation of prolyl residues. This process is primarily controlled by a family of oxygen-
dependent prolyl hydroxylases (PHDs; including PHD1, PHD2, and PHD3), whose 
enzymatic activity is regulated by oxygen availability. In fact, they use molecular oxygen, 
2-oxo-glutarate and iron to hydroxylate these residues within the oxygen-dependent 
degradation domain (ODD) of HIF-1α (Figure 1.1). The product of the von Hippel-Lindau 
tumor suppressor gene (pVHL) then binds to these hydroxyproline residues38. Additionally, 
acetylation of lysine in the same domain by an acetyl transferase (ARD1) favors the 
interaction of HIF-1α with pVHL39. pVHL binding to a region of ODD of HIF α subunits 
initiates HIF-α proteolysis by acting as the recognition component of a ubiquitin ligase 
complex. Multiple ubiquitin molecules attach covalently to the targeted protein and this 
ubiquitin- tagged substrate is degraded by the 26S proteasome40.  
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Figure 1.1: HIF-1α activating mechanism through prolyl hydroxylases family. 
 
In addition to proteolytic degradation, another oxygen-dependent regulatory mechanism is 
the inhibition of transcriptional activity of HIF-1. In normoxic conditions, the factor 
inhibiting HIF-1 (FIH-1), β-hydroxylates the asparaginyl-803 residue of C terminal 
activation domain of HIF-1α, which is the interaction site for the transcriptional co-activator 
p300 therefore prevents the interaction of HIF-1α with co-activators41. Under hypoxic 
condition, HIF-1α becomes stabilized, translocates from the cytoplasm to the nucleus, and it 
heterodimerizes with HIF-1β42. This hypoxia-induced nuclear translocation of HIF-1α 
protects HIF-1α from VHL-mediated proteasomal degradation. In addition, a distinct 
hypoxia-dependent signal is required for stabilization of HIF-1α43. The heterodimerization 
forms a transcriptionally active HIF complex, which in turn associates with hypoxia 
responsive elements (HRE) in the regulatory regions of target genes and binds to 
transcriptional co-activators to induce gene expression (Figure 1.2). Among three HIF α 
isoforms, HIF-1α and HIF-2α are closely related and their transcriptional activities are both 
through interaction with hypoxia responsive elements of target genes44. 
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Figure 1.2: Molecular mechanisms of HIF-1α activation; Weidermann A et Al45. 
 
One of the mediators of hypoxic stress is p53; after oxygen deprivation p53 is stabilized via 
several post translational modifications46. Increased p53 levels lead to increased expression 
of genes involved in cell cycle arrest, such as p21 and ultimately to the expression of genes 
involved in apoptosis47. Counteracting p53 action is another mediator of the hypoxic 
response, Hypoxia Inducible Factor 1 (HIF-1) that promotes the transcription of genes 
involved in adaptation to low oxygen levels through one or more Hypoxia Resposive 
Element (HRE) in their promoters. Recent studies, including ours, proved that p53 and HIF-
1 compete for the co-activator p300 and by doing so they antagonize each other until the 
integration of different signals reaches its balance and the fate of the cell is determined48 
(Figure 1.3). 
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Figure 1.3: Mechanisms of HIF-1α and p53 activation under hypoxia. Frontini M et Al49. 
 
1.7 HIF-1 targeted genes 
Transfer of hydrogen atoms and electrons to molecular oxygen is the final stage of oxidative 
phosphorylation, which is the most important mechanism of energy (ATP) production in 
mammalian cells. Consequently, intracellular O2 concentrations are precisely regulated in 
order to maintain cellular and systemic function. HIF-1 transcriptional complex plays an 
essential role in cellular and systemic oxygen homeostasis by inducing transcription of more 
than a hundred hypoxia responsive genes (Figure 1.4). For instance, a previous study 
demonstrated that more than 2% of all human genes are directly or indirectly regulated by 
HIF-1 in arterial endothelial cells50. The genes regulated at the transcription level by HIF-1 
are involved in a wide-spectrum of cellular functional events, including angiogenesis, 
vascular reactivity and remodeling, vasomotor control, glucose and energy metabolism, 
erythropoiesis, iron homeostasis, pH regulation, cell proliferation and viability, nucleotide 
metabolism, matrix metabolism, and metal transport51. Many of these functional processes 
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are related to homeostatic responses to low oxygen tension. Moreover, hypoxia is not the 
only inducer for the transcriptional activity of HIF-1 in living cells. This is because PHDs 
are dependent on iron as well as molecular oxygen. The displacement of iron by cobaltous 
ions or iron chelators inhibits the catalytic activity of the enzymes, which results in the 
hypoxia-independent activation of HIF52. In addition, several other non-hypoxic factors 
such as growth factors, interleukin 1, prostaglandin E2, thrombin, angiotensin II, serotonin, 
acetylcholine, thrombin, platelet-derived growth factor and nitric oxide donors may also 
induce HIF-1 activation53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Different pathways by which HIF activation regulates the cell response to 
hypoxia and ischemia. 
 
1.8 HIF-1 and cardioprotection 
The role of HIF-1 in mediating cardioprotection was first demonstrated by Cai et al in 
200354. Intermittent systemic hypoxia occurs in many common physiological and 
pathophysiological conditions in human life, which could be caused by environmental 
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factors (e.g. high altitude) or by various cardiopulmonary disorders (e.g. heart failure, 
chronic obstructive pulmonary disease, and sleep apnea) and hematological diseases (e.g. 
anemia)55. In fact, the intermittent exposures to hypoxia are much more frequently than 
chronic exposure to hypoxia. Interestingly, a few well-controlled protocols of intermittent 
hypoxia can induce protective effects against myocardial infarction in rodents via a 
signaling mechanism that depends upon inducible nitric oxide synthase (iNOS)56. Since 
iNOS gene has the HRE in its promoter region and HIF-1 is essential for the hypoxic 
regulation of iNOS gene expression in cardiomyocytes, it is logical to speculate a role for 
HIF-1 in intermittent hypoxia-induced cardioprotection. This concept was experimentally 
proved first by Cai and colleagues who demonstrated that the cardioprotective effect of 
intermittent hypoxia is dependent on HIF-1α gene dosage in wild-type mice, indicated by 
better left ventricular contractile function and significantly smaller infarct size following 
ischemia-reperfusion in the animals pretreated with intermittent hypoxia. Moreover they 
found that in the heterozygous HIF-1α knockout mice, exposure to intermittent hypoxia 24 h 
before lethal ischemia had no protective effect on functional recovery or infarct size. More 
recently, Belaidi et al showed in a rat model that intermittent hypoxia induced delayed 
cardioprotection against ventricular post-ischemic contractile dysfunction and myocyte 
necrosis was mediated by upregulation of iNOS via HIF-157. Interestingly HIF-1α is also 
proposed as involved in the mechanism of intermittent hypoxia induced right ventricular 
protection against ischemia-reperfusion injury of right ventricle58. 
 
1.9 Angiogenesis and other factors in anti-ischemic cardioprotection mediated 
by HIF-1 
The substrate preference of ischemic heart shifts from fatty acid to glucose utilization. The 
role of HIF-1α is important in the early phase of stress response where a transition from 
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aerobic to anaerobic metabolism occurs. HIF-1α controls the factors in glucose metabolism 
which allows cells to shift from aerobic metabolism to anaerobic glycolysis. HIF-1α also 
affects mitochondrial metabolism by inducing pyruvate dehydrogenase kinase, which 
prevents entry of pyruvate into mitochondria, thus reduces mitochondrial respiration, and by 
altering composition of the cytochrome oxidase complex59. In addition, a previous study 
suggested that the adenovirus mediated expression of constitutively stable, hybrid HIF-1α 
protects cultured neonatal cardiomyocytes against simulated ischemia-reperfusion injury by 
inducing multiple protective genes60. Furthermore, the levels of HIF-1α and VEGF increase 
in the myocardium when patients develop acute coronary artery occlusion. The increased 
VEGF expression by HIF-1α could induce coronary angiogenesis in myocardium, which in 
turn provides an enhanced capacity for coronary blood flow and oxygen supply to cardiac 
muscle during myocardial ischemic/hypoxic events61. 
 
1.10 Cardioprotection by pharmacological activators of HIF-1 
Cobalt chloride 
Xi and colleagues were the first to discover the cardioprotective effects induced by CoCl262. 
They found that a single low dose of CoCl2 induced delayed cardioprotection through 
selective activation of HIF-1α, AP-1, and iNOS, without affecting another key transcription 
factor — nuclear factor kappa B in mice. These findings were conceptually confirmed by 
others in a translational model of myocardial ischemia-reperfusion injury following deep 
hypothermic circulatory arrest in neonatal piglets. CoCl2 pretreatment significantly 
attenuated myocardial apoptosis and the cardioprotective effects were associated with 
enhanced cardiac expression of phosphorylated Akt and anti-apoptotic protein Bcl-2 and 
decreased expression of pro-apoptotic protein Bax63. 
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Prolyl hydroxylase inhibitors 
Another therapeutic method is increasing endogenous HIF-1 level or activity by blocking 
HIF-1 inhibitors during normoxia or by increasing the HIF-1 stabilizing agents, which is 
partially discussed above under pharmacological preconditioning. Inhibition of HIF 
hydroxylases by 2-oxoglutarate analogs stabilizes HIF and thus hypoxia responsive genes 
are activated64. Inhibition of EGLN1/PHD prolyl hydroxylase led to tissue preservation in 
the rats undergoing myocardial infarction. Furthermore, HIF-1 activation through PHD 
inhibition by dimethyloxalylglycine (DMOG) before I/R attenuates tissue injury in rabbit 
hearts65. Cardioprotection by iron chelator deferoxamine is also associated with inhibition of 
PHDs66. These investigators also showed that upregulation of HIF-1α was upregulated with 
deferoxamine (150 mg/kg/day for 2 days), which led to better reserved contractile functional 
and calcium transient in the cardiomyocytes exposed to simulated ischemia-reoxygenation 
in response to positive inotropic agents. Most recently, chronic post-myocardial infarction 
treatment with a novel orally active potent PHD inhibitor - GSK360A (30 mg/kg/day for 28 
days, po) led to a long-term improvement in left ventricular contractile function, 
remodeling, and vascularity in a rat model of ischemia-induced heart failure. These 
protective effects were associated with a significant increase of the HIF-1α regulated 
cardioprotective molecules such as HO-1 and EPO67. 
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CHAPTER 2: Aim of the Study 
Medical, surgical and transplantation therapies are largely ineffective to successfully cure 
the growing number of patients affected by HF. Therefore, novel translational approaches 
have been developed in the past decade in order to better understand the cellular and 
molecular basis of the disease, with the ultimate goal of developing new therapeutic 
strategies. 
One of the key issues to be solved is that the ischemic/hypoxic condition in HF determines 
several functional consequences that ultimately lead to cellular death and irreversible 
damage to cardiac myocytes. 
Based on these premises, the main aim of this Ph.D. work was to develop a new approach 
for the activation and the exploitation of the physiological cellular response to hypoxic 
stress. In fact, under hypoxic conditions, cells activate several protective (pro-survival and 
anti-apoptotic) pathways mainly regulated by the transcription factor HIF-1α. In particular, 
based on some preliminary results preceding the beginning of this Ph.D. work, we decided 
to investigate the role of sialidase NEU3 in the regulation of the cellular response to 
hypoxia, through a novel mechanism of activation of HIF-1α. In fact, as described in the 
following chapter, sialidase NEU3 is a glycohydrolytic enzyme that is bound to the outer 
leaflet of the plasma membrane, and it has been shown to play a crucial role in many 
cellular processes, including cell proliferation and differentiation. In particular, it has been 
reported an activation of the enzyme in cancer, which eventually leads to the activation of 
pro-survival pathways, with concomitant suppression of apoptosis.  
To this purpose, the first step of this Ph.D. work was to develop an in-vitro model of 
ischemia to test this hypothesis. Thus, murine skeletal myoblasts were engineered by 
overexpressing or silencing NEU3, subjected to hypoxic conditions in vitro, and then the 
effects compared to wild-type myoblasts under the same experimental conditions.  
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In a second phase of this Ph.D. work we sought to test the scope of the newly discovered 
model to other cell types, and in particular to human cardiomyocytes, as they are mainly 
affected during heart failure. 
Unfortunately, culturing human adult cardiomyocytes in vitro is practically unfeasible, thus 
we had to develop a new strategy. In fact, as described in the following chapters, we 
evaluated NEU3 activation using two different models:  
- A model of acute cardiac ischemia, that we achieved by analyzing heart specimens 
obtained during aortic cross-clamp time and extracorporeal circulation in adult 
patient submitted to cardiac surgical procedures. 
- A model of chronic hypoxia, that we could achieve by analyzing heart specimens of 
neonates and young patients operated for cyanogen congenital cardiac defects. 
Both models could be developed in the Cardiac Surgery Unit of IRCCS Policlinico San 
Donato, where both type of surgeries were performed directly by myself and other surgeons, 
under the supervision of Dr. L. Menicanti and Dr. A. Frigiola. 
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CHAPTER 3: In-Vitro model of Skeletal Muscle Cells Ischemia 
3.1 Introduction: Role of the Sialidases 
Sialidases, also known as neuraminidases, belong to a group of glycohydrolytic enzymes, 
which remove sialic acid residues from a variety of sialoglycoconjugates. They are widely 
distributed among the different classes of organisms such as viruses, bacteria, protozoa and 
vertebrates68. Sialidases are thought to be involved in various biological processes like 
infection, proliferation, differentiation, catabolism, signal transduction, antigenic properties 
and inter–intra cell interactions69. Several mammalian sialidases have been cloned and 
characterized at the molecular level. In humans, four types of sialidases are known and have 
been classified based on their subcellular localization as intra lysosomal (NEU1)70, cytosolic 
(NEU2)71, plasma membrane (NEU3)72 and lysosomal or mitochondrial membrane 
(NEU4)73 (Figure 3.1)  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Cellular localization of mammalian sialidases 
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Lysosomal sialidase (NEU1) possesses narrow substrate specificity for oligosaccharides, 
glycopeptides and a synthetic substrate 4MU-Neu5Ac (4-methylumbelliferyl-N-
acetylneuraminic acid) and is involved in lysosomal catabolism of sialoglycoconjugates by 
collaborating with lysosomal proteases or endoglycosidases74. Lysosomal storage diseases 
like sialidosis and galactosialidosis caused by NEU1 deficiency, interferes with the 
pathways for degradation of sialylated glycoconjugates75. In addition to this NEU1 has been 
proposed to be involved in cellular signaling during immune responses as well as monocytes 
differentiation76. 
Cytosolic sialidase (NEU2) is active against oligosaccharides, glycopeptides and perhaps 
gangliosides. In mammals, it has been implicated in myotube formation77. The exact 
mechanism of myoblast differentiation through its natural substrate remains obscure but it is 
claimed to decrease the GM3 ganglioside content, associated with the cytoskeleton.  
Plasma membrane sialidase (NEU3) hydrolyzes gangliosides specifically (except GM1 and 
GM2) in presence of non-ionic surfactant (Triton X-100)78. Since gangliosides are abundant 
on the plasma membrane and are known modulators of several surface events like cell 
differentiation, cell proliferation and signal transduction, NEU3 has been shown to be 
involved in cell surface functions mainly by modulating ganglioside relative content in the 
lipid rafts. The enzyme is linked to the plasma membrane and has been shown to possess 
trans-activity because it can also work on the gangliosides present on the plasma membrane 
of adjacent cells. These key features are likely instrumental for a crucial role played by the 
enzyme in many cellular processes, including cell proliferation and differentiation. In 
particular, the increase of sialidase expression and activity during skeletal muscle 
differentiation has been shown to drive the process, protecting myoblasts from apoptosis79. 
Moreover, an induced overexpression of NEU3 renders murine myoblasts more resistant to 
cell cycle withdrawing and accelerates the differentiation process, ultimately increasing cell 
fusion. Finally, NEU3 has been also shown to positively participate to the differentiation 
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process leading to neurite formation in mice80 and to the regulation and regeneration of rat 
hippocampus neurons81. 
Lysosomal or mitochondrial membrane sialidase (NEU4) has broad specificity, active 
against all major sialoglycoconjugates and has been implicated in the catabolism of 
glycolipids82. A recent report reveals the possibility of NEU4 being involved in apoptosis 
pathway at the mitochondrial level by regulating ganglioside GD3. Further functions of 
NEU4 are yet to be explored. 
 
3.2 Development of an in-vitro model 
We have previously described that NEU3 sialidase plays a key role in many cellular 
processes, including cell proliferation and differentiation83. However, it should be noted that 
activation of pro-survival pathways induced by NEU3, with concomitant suppression of 
apoptosis, has been mostly reported in pathological conditions84. For instance, NEU3 
aberrant overexpression has been observed to occur in several neoplasms (including colon, 
ovarian, renal, and prostate cancer) and is considered to be one of the key triggers of tumor 
growth and invasiveness. In this PhD project we wanted to investigate the physiologic role 
of NEU3 on cellular homeostasis, with particular emphasis on the possible involvement of 
NEU3 in cell response to hypoxic stress and in cell machinery opposing cell death. To this 
purpose, the first step was to develop an in-vitro model of murine skeletal myoblast 
ischemia in order to investigate NEU3 expression and activity under hypoxic stress. 
Secondly, the enzyme was stably overexpressed or silenced in murine skeletal myoblasts 
C2C12, which were then cultured under hypoxic conditions (1% Oxygen), and the results 
compared with those of wild-type C2C12. 
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3.3 Materials and Methods	
Cell culture  
C2C12 mouse myoblasts were obtained from the American Type Culture Collection 
(ATCC) and cultured in Dulbecco’s modified Eagle’s medium with high glucose (DMEM) 
supplemented with 10% (v/v) fetal bovine serum (FBS), 4 mM L-glutamine, 100 U/ml 
penicillin, and 100 µg/ml streptomycin at 37°C in 5% CO2, 95% air-humidified atmosphere.  
Stable overexpression or silencing of sialidase NEU3 in C2C12 myoblasts 
Silencing of NEU3 in C2C12 cells was achieved by designing a short hairpin targeting the 
mouse NEU3 gene sequence 894-914 (5-GCACCATGGCAAGTTCATTGA-3), 
(GenBankTM accession no. NM_016720) with the Block-iT RNA iDesigner Software 
(Invitrogen). Overexpression of NEU3 in C2C12 cells was obtained by cloning the entire 
NEU3 gene into the plasmid vector pLenti6.3/V5-TOPO® (Thermo Fisher Scientific). Viral 
particles were formed by transfecting 3 µg of pLenti4/BLOCK-iT-shNEU3 vector or 
pLenti6.3/V5-TOPO® NEU3 vector and 9 µg of packaging vector mix (Virapower, Thermo 
Fisher Scientific) in 293FT cells by Lipofectamine® 2000 reagent (Thermo Fisher 
Scientific). After 48 hours, the culture medium was collected and used to infect proliferating 
C2C12 cells (multiplicity of infection of 5) according to the manufacturer’s procedure. 
Infected clones were isolated after selection with Blasticidin (3 mg/ml). NEU3-silenced 
cells were named “iNEU3” cells, whereas overexpressing cells were named “L-NEU3”. 
 
Chemical or physical hypoxic treatment 
For the 1% O2 hypoxia experiments, cells were cultured at 37°C in 5% CO2, 1% O2 
incubator with nitrogen inlet. For chemical hypoxia, 100 µM deferoxamine (DFO, Sigma) 
was dissolved in the culture medium at the cells were treated for 6 – 24 – 48 – 72 hours. 
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Cell growth analysis 
2 x105 C2C12, L-NEU3 or iNEU3 cells were seeded in 100 mm culture dishes and viable 
cells were counted with the Countess Automated Cell Counter (Thermo Fisher Scientific) 
every 24 hours up to 3 days using the vital stain Trypan Blue. 
 
RNA extraction and retro-transcription in cDNA 
Total RNA was isolated with RNeasy Mini Kit® (QIAGEN), following the protocol 
suggested by the manufacturer. mRNA quantity and purity were assessed by reading 
absorbance at 260 nm wavelength with a spectrophotometer Nanodrop (EuroClone). We 
considered suitable the samples with the following ratio: 
• A260/A280 greater than 1,9 that means no contamination by proteins 
• A260/A230 greater than 1,9 that means no contamination by carbs or phenol, which 
could affect retro-transcription efficacy. 
All the samples satisfied both the aforementioned conditions. After isolation and 
purification, 1 µg of RNA was reverse-transcribed to cDNA using the iScript cDNA 
Synthesis Kit (Bio-Rad Laboratories) according to the manufacturer’s instruction.  
Briefly, for every sample the reaction mix was prepared as follow: 
 
 
 
 
 
 
The samples were reverse transcribed in a thermocycler using the following protocol:  
 5 minutes at 25°C; 30 minutes at 42°C; 5 minutes at 85°C and resting at 4°C 
 
Reaction Mix 4  µL 
Reverse transcriptase 1  µL 
RNA µL equivalent to 1 µg 
H2O µL to fill the volume 
Final Volume 20  µL 
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Gene expression analysis by Real Time PCR 
The quantitative expression of the genes of interest was assessed by Real Time PCR.  
Initially, the specific primers to evaluate the expression of the genes of interest have been 
designed with the “Primer3” software and then checked with the “Blastn” program to 
control their correct annealing with the identified target genes.  
For the analysis the following primers have been used: 
PRIMER MELTING T (°C) SEQUENCE 
β-actin 57 
Fw- AGAGGGAAATCGTGCGTGAC 
Rev- CTCGTTGCCAATAGTGATGACC 
NEU3 57 
Fw- TGCGTGTTCAGTCAAGCC 
Rev- GCAGTAGAGCACAGGGTTAC 
HIF-1α 57 
Fw- CGCTATCCACATCAAAGCAA 
Rev- GCACTAGACAAAGTTCACCTGAGA 
SP1 57 
Fw- ATGCCCCTATTGCAAAGACA 
Rev- TGGATGTGACAAATGTGCTG 
SP3 57 
Fw- TGGTAAAAGATTTACACGAAGTGATG 
Rev- GGACAAACAAACTTCTTCTCACC 
The single Real-Time PCR reactions were performed in a 96 well plate, mixing in a final 
volume of 20 µL the following reagents: 
• cDNA; 10 ng 
• Primers mix; 0,2 µM 
• 1X iQ SYBR Green Supermix (Bio-Rad Laboratories) containing: Sybr Green, Taq 
polymerase (0.6 U), MgCl2 (3 mM), Buffer (Tris/HCl 20 mM, KCl 50 mM, pH 8.4), 
dNTPs (200 µM). 
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The PCR reaction was performed under the following conditions: 
• Initial denaturation: 95°C for 2 minutes (1 cycle) 
• Denaturation: 95°C for 30 seconds 
• Annealing: 57°C for 30 seconds 
• Elongation, fluorescence detection: 72°C for 30 seconds 
• Final Elongation: 72°C for 2 minutes 
The three steps (denaturation, annealing and elongation) were repeated for 40 cycles.  
The fold-change in expression of the different genes in L-NEU3 and i-NEU3 cells compared 
to control C2C12 was normalized to the expression of β-actin mRNA and was calculated by 
the equation 2-ΔΔCt with iQ5 Software Version 2.0 (Bio-Rad Laboratories). All reactions 
were performed in triplicate and the accuracy was monitored by analysis of the PCR-
product’s melting curve.  
 
Sialidase activity assay 
Wild-type C2C12 cells, L-NEU3 and i-NEU3 cells were harvested by centrifugation at 2000 
rpm for 10 minutes at 4°C and resuspended in PBS containing 1 mM EDTA, 1 µg/ml 
pepstatin A, 10 µg/ml aprotinin and 10 µg/ml leupeptin. Total cells suspensions were lysed 
by sonication (2 cycles of 10 burst each) and then centrifuged at 800 rcf for 10 minutes to 
eliminate unbroken cells and nuclear components. The obtained supernatants were 
subsequently centrifuged at 200000 rcf at 4°C for 20 minutes on a TL100 Ultracentrifuge 
(Beckman) to obtain cytosolic and particulate (or membranes) fractions.  
The sialidase activity present in the particulate fraction was assayed by a fluorimetric assay 
using 4-MU-NeuAc (4-methylumbelliferyl N-acetylneuraminic acid). The activity was 
expressed as U/mg protein: 1U equals to 1µmole of substrate released in 1 minute. 
The reaction mixture for each sample was prepared as follow: 
• 50 mM Citrate phosphate buffer, pH 3.8 
• 0,1 mM MU-NeuAc 
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• 600 µg BSA 
• 30 µg of membrane proteins containing the enzyme 
The mixture was brought to a final volume 100 µl with H2O. 
The samples were incubated at 37°C, with shaking, for 1 hour. At the end of the incubation, 
the reaction was sopped by the addiction of 1,5 ml of 0,2 M glycine pH 10.8 for each 
sample. The amount of 4-methylumberilliferyl released by the enzyme was determined by 
measuring the fluorescence emitted. The fluorescence was determined using a Nanodrop 
fluorometer (excitation: 365λ emission: 448λ).  
 
Protein expression analysis by Western Blot 
Western blot is often used in research to separate and identify specific proteins. In this 
technique a mixture of proteins is separated by gel electrophoresis in the presence of 
Sodium Dodecyl Sulphate (SDS) and transferred to a membrane that, at a later stage, will be 
incubated with antibodies specific for the proteins of interest. This technique allows to 
identify not only the presence/absence of a specific protein but also to determine its 
molecular weight and relative quantitative expression.  
Cells were lysed in ice-cold lysis buffer, containing 1% of nonylphenoxypolyethoxylethanol 
(NP40, Sigma) in 50 mM Tris-HCl at pH 7.5; 150 NaCl; 0.1% sodium deoxycholate; 1X 
protease inhibitor cocktail and 1X phosphatase inhibitor cocktail (Sigma). Lysates were 
incubated for 30 minutes on ice and centrifuged at 14000 rcf for 10 minutes at 4°C.  
Before separating proteins by SDS-electrophoresis, their concentrations were measured by 
the Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific) following the 
manufacturer’s protocol. 30 µg of proteins were denatured by boiling for 5 minutes in 
sample buffer (62,5 mM Tris-HCl pH 6.8, 2% SDS (w/v), 10% glycerol (v/v), 5% 2-
mercaptoethanol (w/v), 0,01% bromophenol blue (w/v)) and separated on a 10% 
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polyacrylamide gel in denaturing conditions.  A discontinuous gel has been prepared 
composed by the stacking and the running gels.  
Stacking Gel Composition 
• Deionized water 
• Tris-HCl 1.5 M, pH 6.8 
• SDS 0.1% w/v 
• Acrylamide 4% 
• APS 10% w/v 
• TEMED 
10% Running Gel composition 
• Deionized water 
• Tris-HCl 1.5 M, pH 8.8 
• SDS 0.1% w/v 
• Acrylamide 10-12% 
• APS 10% w/v 
• TEMED 
Proteins were subsequently transferred onto nitrocellulose membranes by electroblotting 
using 100 Volt for 2 hours. Then, the membranes were incubated overnight in Tris-buffered 
saline (TBS: 10 mM Tris-HCl, pH 7.4, 150 mM NaCl), 0.1% (v/v) Tween 20 (TBS-Tween) 
containing 5% (w/v) dried milk or 5% (w/v) bovine serum albumin (BSA; Sigma) for the 
blocking buffer. Blots were incubated with a primary antibody in the appropriate blocking 
solution for 3 hours at room temperature.  
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The primary antibodies used for the analysis were the following: 
 
PRIMARY ANTIBODY DILUTION MANUFACTURER 
EGFR 1:1000 Cell Signaling ® 
p-EGFR 1:1000 Cell Signaling ® 
AKT 1:100 Santa Cruz ® 
p-AKT 1:100 Santa Cruz ® 
HIF-1α 1:1000 Novus Biologicals ® 
p70S6K 1:1000 Cell Signaling ® 
p-p70S6K 1:1000 Cell Signaling ® 
β-actin 1:5000 Abcam ® 
 
The membrane were washed 4 times for 10 minutes with TBS-Tween and then incubated 
with the appropriate secondary antibody conjugated with horseradish peroxidase (HRP) for 
1 hour at room temperature. After 4 washes in TBS-Tween, the protein bands were detected 
using an ECL detection kit (Thermo Fisher Scientific) as described by the manufacturer. 
 
Treatment of cell cultures with [3-3H]-Sphingosine 
The determination of the ganglioside pattern of wild-type C2C12, L-NEU3 and i-NEU3 
cells was accomplished by radioactive metabolic labeling with [3-3H]-Sphingosine (Perkin 
Elmer).  
[3-3H]-Sphingosine is a natural precursor of sphingolipids. When cells are placed in culture 
medium supplemented with radiolabeled sphingosine, it is absorbed and used into the 
biosynthetic pathways of sphingolipids. The metabolic products are radioactive, and after 
extraction and separation by HPTLC, it is possible to evaluate the cellular sphingolipid 
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content in terms of both quality and quantity. 
[3-3H]-Sphingosine was dissolved in methanol, transferred into a sterile glass tube, and then 
dried under a nitrogen stream. The residue was dissolved in an appropriate volume of pre-
warmed (37°C) 10% fetal bovine serum DMEM medium to obtain a final sphingosine 
concentration of 3 x 10-8 M (corresponding to 0.4 µCi/100 mm dish). The solution was 
sonicated for 2 minutes and vortexed for 1 minute. This procedure was repeated 3 times. 
The degree of solubilization (> 70%) was verified by counting theradioactivity by β-counter 
(Perkin Elmer).  
A total of 1 x 106 cells were incubated in this medium for a 2 hours pulse followed by a 24 
hours chase, a condition warranting a steady-state metabolic condition. At the end of the 24 
hours chase, cells were harvested and lyophilized for the lipids extraction and analysis. 
 
Lipid extraction and analysis 
The lyophilized cells were resuspended in 25 µl of water, sonicated in ultrasonic bath and 
vortexed. In order to obtain a good solubilization, two lipid extractions were made. 
• First extraction 
10 volumes of methanol were added to the aqueous solution of cells. The resulting mixture 
was sonicated in ultrasonic bath for 2 minutes and vortexed for 1 minute. Then, 20 volumes 
of chloroform were added. Sonication in ultrasonic bath for 2 minutes and agitation were 
repeated. The samples were shaken on an Eppendorf shaker for 10 minutes and centrifuged 
at 10000 rcf for 10 minutes at room temperature. The supernatant containing the lipids was 
transferred to a new eppendorf.  
• Second extraction 
10 volumes of a mixture of chloroform/methanol 2:1were added to pellet. The samples were 
sonicated in ultrasonic bath, vortexed and shaken for 10 minutes; then, samples were 
centrifuged at 10000 rcf for 10 minutes at room temperature. The lipid supernatant was 
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collected and combined with that collected after the first extraction. The protein pellets, 
after the evaporation of solvent, were digested overnight at room temperature in 50 μl of 1N 
NaOH and subsequently, brought to 1 ml with water. Protein concentration was then 
measured by the Lowry method. The lipid radioactivity was evaluated to determine the 
percentage yield of the lipid extraction. 
• Partition of lipids 
This procedure allows to divide the extracted lipid in an aqueous phase (FA), containing 
gangliosides, and an organic phase (FO), containing neutral glycolipids.  
The partition was divided into two phases: 
• First partition 
In order to separate the aqueous from the organic phase, a volume of water equal to 20% of 
the total solution was added to lipid extracts. Samples were vortexed and mixed on a 
Eppendorf mixer for 15 minutes and centrifuged at 3500 rcf for 5 minutes. The aqueous 
phase was collected and transferred to a new eppendorf. 
• Second partition 
A mixture of methanol/water 1:1, equal to 40% of the initial volume, was added to the 
organic phase. The separation of the aqueous phase from the organic phase was obtained by 
vortexing and agitation on an Eppendorf shaker for 15 minutes and, finally, centrifugation at 
3500 rcf for 5 minutes. The aqueous phase was collected and added to the one obtained in 
the first separation. The two separated phases were dried under nitrogen stream and 
suspended in a mixture of chloroform/methanol 2:1. The aqueous phase was resuspended in 
100 μl of solvent, while the organic phase was resuspended in 200 μl. Radioactivity assays 
of the two phases were performed to determine the percentage yield of the partition. Neutral 
glycolipids of the organic phase were then separated by HPTLC using a 
chloroform/methanol/water (110:40:6 (v/v/v)) solvent system whereas gangliosides were 
separated by a chloroform/methanol/0.2% aqueous CaCl2 (60:40:9 (v/v/v)) solvent system. 
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[3-3H]-Sphingolipids were identified by referring to radiolabeled standards and quantified 
by radiochromatoimaging (Beta-Imager 2000, Biospace). The content of the component 
detected was expressed as dpm/mg of total proteins.  
 
Silencing of GM3 Synthase by siRNA Transfection 
Specific siRNA duplexes targeting GM3 synthase, siRNA transfection reagents, and 
reduced-serum transfection medium were purchased from Santa Cruz Biotechnology. The 
day before transfection, 2x105 C2C12 myoblasts were seeded in each well of a 6-well cell 
culture plate in DMEM containing 10% FBS without antibiotics and incubated for 24 hours 
at 37°C and 5% CO2. The next day, transfection complexes were prepared using GM3 
synthase siRNA, siRNA transfection reagent, and transfection medium according to the 
manufacturer’s protocol and were added to each well. The final concentration of GM3 
synthase siRNA duplexes used was 3µg .A scrambled siRNA (Santa Cruz Biotechnology) 
was used as negative control. GM3 synthase primers: forward, 5’-
TTCTGGGGCCATGATAAGAA-3’ and reverse 5’-TGACTGAGGTCGTAGCCAAA-3’. 
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3.4 Results 
Effects of Hypoxia on Wild-type C2C12 Proliferation and NEU3 Expression and Activity 
Wild-type C2C12 cells were cultured for 72 h in 1% oxygen or DFO, which is widely used 
at this concentration to chemically mimic hypoxia by chelating iron. The final concentration 
of 100 µM was chosen because it was more toxic than 1% oxygen, but not completely 
lethal, and could allow us to test NEU3 effects under severe hypoxic stress. Exposure to 1% 
oxygen caused a marked reduction of proliferation compared with untreated C2C12. DFO 
treatment caused massive cell death, as only few cells were alive after a 72 h treatment, and 
widespread cell debris could be observed in the culture plates. NEU3 expression, measured 
by qPCR, underwent a progressive and remarkable increase during 1% O2 or DFO 
treatment. NEU3 activity increased markedly over time during exposure to 1%O2 and, to a 
minor extent, upon DFO treatment. NEU3 activity with DFO could not be determined at 72 
h due to the massive extent of cell death (Figure 3.2). 
36	
	
 
 
Figure 3.2. Effects of hypoxia on C2C12 cell proliferation and NEU3 expression and 
activity. Proliferating C2C12 cells were cultured for 24, 48, and 72 h in normoxia or in 1% 
O2 and 100 µM DFO hypoxic conditions. A, cell growth curves. B, NEU3 expression by 
qPCR. C, NEU3 activity on 4-MU-NeuAc. All data are means±S.D. of three different 
experiments. Statistical differences were determined by one-way ANOVA. **, p<0.001; 
***, p<0.0001 compared with initial values. D, phase-contrast microscopic images at 10x 
magnification. 
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Effects of NEU3 Sialidase Overexpression and Silencing on C2C12 Proliferation under 
Hypoxia 
C2C12 cells were transduced with a lentiviral vector containing the murine NEU3 sialidase 
gene. Among five clone tested, clone 2 (hereafter named L-NEU3) showed the highest 
sialidase expression, which was 19-fold higher than in C2C12, whereas sialidase activity 
was approximately 3-fold higher. C2C12 cells were also transduced with a lentiviral vector 
engineered to silence NEU3 with a shRNA targeting the coding region of the enzyme. The 
selected clone, hereafter named i-NEU3, showed the lowest sialidase expression levels, 
quantified as a 2.5-fold reduction compared with wild-type C2C12, whereas sialidase 
activity displayed a 3-fold decrease. C2C12, L-NEU3, and i-NEU3 cells were then cultured 
for 3 days in normoxia, or 1% oxygen, or 100 µM DFO and analyzed for cell growth. As 
shown in Figure 3.3, under normoxic conditions cell growth was slightly higher 
(approximately 15% after 3 days) in L-NEU3 compared with C2C12 cells, whereas in i-
NEU3 cells it was much lower (approximately 40% less). In 1% O2 conditions, L-NEU3 
cells had a proliferation reduction after 3 days in culture which was much lower than control 
C2C12 cells (33% versus 58%), whereas i-NEU3 cells underwent a drop in proliferation 
close to 90%. Upon DFO treatment, proliferation appears to be blocked in all cell types, 
with a cell survival after 3 days of 80% for L-NEU3 cells, 30% for C2C12 cells, and 27% 
for i-NEU3 cells. Panels D in Figure 3.3 show that L-NEU3 cells reached confluence after 
3 days culture in normoxic conditions, as well as at 1% O2, but little proliferation occurred 
in DFO. By contrast, i-NEU3 cells exhibited clear signs of massive cell death in both 1%O2 
and DFO because many dead cells could be found floating in the culture dish. 
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Figure 3.3: Effects of NEU3 overexpression or silencing on C2C12 resistance to hypoxic 
conditions. A, qPCR analysis of NEU3 mRNA expression levels. B, NEU3 activity on 4-
MU-NeuAc. Data are means±S.D. of three different experiments, significance according to 
two-way ANOVA. **, p<0.001; ***, p<0.0001 compared with wild-type C2C12 cells. C, 
growth curves of cells cultured in normoxia, 1% oxygen and 100 µM DFO. D, phase-
contrast microscopy (10x magnification) of L-NEU3 and i-NEU3 cells cultured in 
normoxia, 1% O2, and 100 µM DFO for 72 h. 
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Sphingolipid Pattern Analysis 
The glycosphingolipid profile of control C2C12, L-NEU3, and i-NEU3 cells was 
determined by administration of [3-3H]sphingosine, which led to an extensive and stable 3-
3H-labeling of cell sphingolipids, namely gangliosides, neutral glycosphingolipids, 
sphingomyelin, and ceramide, at steady-state conditions. Analysis of the ganglioside pattern 
revealed a 35% reduction ofGM3in L-NEU3 cells, whereas a 2-fold increase of the same 
ganglioside could be observed in i-NEU3 cells, making GM3 approximately 97% of the 
total ganglioside content. (Figure 3.4, A and B). However, no significant variation could be 
detected for the other major gangliosides in L-NEU3 cells, whereas i-NEU3 showed a 
significant reduction in GM2 (-89%) and GD1a (-96%). Conversely the radioactive patterns 
of the sphingolipids contained in the organic phase did not exhibit significant differences 
upon overexpression or silencing of NEU3, with only a minor increase of GlcCer, LacCer, 
and SM in L-NEU3 cells (Figure 3.4, C and D). 
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Figure 3.4: Effects of NEU3 activity on the sphingolipid pattern. Proliferating C2C12, 
L-NEU3, and i-NEU3 cells were metabolically labeled with [3-3H]sphingosine. A) 
radiochromatoscanning images of HPTLC separation of gangliosides contained in the 
aqueous phase. B) ganglioside distribution expressed as dpm/mg of protein. C) 
radiochromatoscanning images of HPTLC separation of sphingolipids contained in the 
organic phase. D) sphingolipid distribution expressed as dpm/mg of protein. Data of B and 
D represent means±S.D. (error bars) of five different experiments (significance according 
to two-wayANOVA:**, p<0.001 and ***, p<0.0001 compared with wild-type C2C12 cells).  
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NEU3 activation of HIF-1α through the EGFR-mediated signaling pathway 
Analysis of the ganglioside pattern revealed a 35% reduction of GM3 in L-NEU3 cells, 
whereas a 2-fold increase of the same ganglioside could be observed in i-NEU3 cells, 
making GM3 approximately 97% of the total ganglioside content. Because ganglioside 
GM3 is known to inhibit EGFR autophosphorylation, we tested whether NEU3-induced 
reduction of GM3 would affect the activity of key proteins of the EGFR-mediated signaling 
cascade, in their inactive and/or active (phosphorylated) forms, thus leading to regulation of 
HIF-1α expression. Therefore, the levels of these proteins in all three cell-lines (control 
C2C12, L-NEU3, and i-NEU3) under normoxic and hypoxic conditions (1% O2 at 3, 6, and 
24 h) were analyzed by Western blotting. Results revealed that HIF-1α, could not be 
detected in control C2C12 cells grown for 3, 6, and 24 h in normoxia as expected, because 
HIF-1α is degraded under normoxic conditions by the ubiquitin-proteasome system. 
Analogous results were observed in i-NEU3 cells. Conversely, L-NEU3 cells exhibited 
substantial levels of HIF-1α even under normoxia. Upon cell culturing in 1% oxygen, HIF-
1α protein level increased over time in all cells, although in L-NEU3 it reached the highest 
levels. In particular, in L-NEU3 cells, high levels were reached already within 3 h under 
hypoxia, whereas comparable levels were reached by control C2C12 only at 6 h, and by i-
NEU3 at 24 h. Western blot analysis of the EGFR-mediated signaling cascade, leading to 
HIF-1α activation, revealed similar trends, because EGFR, phospho-EGFR, AKT, phospho-
AKT, p70S6K, and phospho-p70S6K were all activated earlier in L-NEU3 cells and 
exhibited higher levels compared with control C2C12. The increments of all measured 
proteins were delayed and exhibited anyhow lower levels in i-NEU3 cells (Figure 3.5). 
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Figure 3.5: Analysis of EGFR-mediated signaling pathway by Western blotting. Total 
proteins from C2C12, L-NEU3, and i-NEU3 cells cultured for 3, 6, and 24 h in 1% O2 
anoxic conditions were stained with anti-HIF-1α (A), anti-EGFR antibody (B), anti-
phospho-EGFR antibody (C), anti-AKT antibody (D), antiphospho-AKT antibody (E), anti-
p70S6K (F), and anti-phospho-p70S6K (G). Changes in protein content were quantified by 
densitometry and are represented in columns. N, normoxic; H, hypoxic. All data are the 
means±S.D. (error bars) of three different experiments. Statistical differences were 
determined by two-way ANOVA. *, p < 0.05; **, p <0.001; and ***, p < 0.0001 compared 
with C2C12 cells. 
43	
	
Silencing of GM3 Synthase 
To test whether the observed effects go through NEU3-induced GM3 depletion and 
consequent EGFR activation, we tested whether we could mimic NEU3 effects by silencing 
GM3 synthase, thus reducing GM3 cell content. To this purpose, wild-type C2C12 were 
transfected with specific siRNA duplexes targeting GM3 synthase. Analysis by qPCR 
revealed a 50% reduction in GM3 synthase expression compared with controls (Figure 3.6-
A). Analysis of the sphingolipid pattern by administration of [3-3H]sphingosine (Figure 3.6 
B and C), revealed a significant decrease of ganglioside GM3, which was approximately 
35% less than controls, whereas both lactosylceramide and globotriaosyl ceramide were 
markedly increased. Analysis of cell growth under normoxia revealed a significant, although 
minimal, increase in cell proliferation in GM3 synthase-down-regulated C2C12 (Figure 
3.6-D). Cells were then subjected to 1%O2 and monitored for 48 h. Cell growth analysis 
showed a significant cell number reduction after 48 h in hypoxia in control C2C12, as 
expected. However, down-regulation of GM3 synthase rendered myoblasts more resistant to 
hypoxia, as we could detect a 25% increase of alive cells after 48 h in hypoxia, compared 
with control cells (Figure 3.6-E). 
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Figure 3.6: Silencing of GM3synthase increases C2C12 resistance to hypoxia. A, qPCR 
analysis of GM3 synthase mRNA expression levels in control and GM3 synthase-silenced 
C2C12 cells. B, radiochromatoscanning images of HPTLC separation of gangliosides 
contained in the aqueous phase. C, radiochromatoscanning images of HPTLC separation of 
sphingolipids contained in the organic phase. Sphingolipid distribution is expressed as 
dpm/mg of protein. Data of B and C represent means±S.D. (error bars) of three different 
experiments. Significance was determined according to two-way ANOVA. ***, p<0.0001 
compared with wild-type C2C12 cells. D and E, growth curves of cells cultured in normoxia 
(D) and in 1% oxygen (E). Data of D and E are means±S.D. of three different experiments. 
Significance was determined according to two-way ANOVA. *, p<0.005; **, p<0.001; and 
***, p<0.0001 compared with wild-type C2C12 cells. 
 
Activation of SP1/SP3 under Hypoxia 
Wild-type C2C12cells were subjected to 1% O2 for 48 h to test the activation of 
transcription factors SP1 and SP3, which have been recently found to bind to NEU3 
promoter region. Analysis of SP1 and SP3 expression by qPCR revealed a significant 
increase of both factors under hypoxia (Figure 3.7, A and B), supporting a possible 
mechanism of endogenous activation of NEU3 under hypoxia (Figure 3.7-C). 
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Figure 3.7: Activation of SP1 and SP3 under hypoxia could lead to NEU3 up-regulation. A 
and B) qPCR analysis of SP1 and SP3mRNAexpression levels in C2C12 cells cultured in 
1% O2 up to 48 h. C) schematic representation of SP1/SP3-mediated activation of NEU3 
sialidase under hypoxia. 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
46	
	
3.5 Discussion 
The experiments performed in this in-vitro model allowed us to draw the following 
conclusions: 
1) Endogenous NEU3 sialidase expression and activity are up-regulated in murine 
skeletal muscle cells (C2C12) upon oxygen starvation, leading to a signaling cascade 
resulting in the activation of HIF-1α.  
2) Moreover, induced overexpression of NEU3 significantly increases HIF-1α 
expression and cell resistance to hypoxic stress, whereas NEU3 silencing causes the 
opposite effects and renders myoblasts more susceptible to apoptosis. 
These data substantiate the hypothesis that NEU3 sialidase, which was found to be activated 
under hypoxic conditions, can activate the EGFR pro-survival signaling pathway by 
controlling the content of ganglioside GM3. To test this hypothesis, the effects of NEU3 
overexpression and silencing were studied on the EGFR signaling pathway. As anticipated, 
NEU3 overexpression causes a reduction of ganglioside GM3, which is known to block 
EGFR autophosphorylation. Therefore, upon NEU3 up-regulation, the net effect is that 
EGFR signaling cascade is activated, as demonstrated by the activation of pro-survival and 
anti-apoptotic signaling molecules down-stream of EGFR, including AKT, p70S6K, and 
ultimately HIF-1α. This causes an increased resistance of myoblasts to hypoxia, ultimately 
opposing apoptotic cell death. Notably, upon NEU3 overexpression, HIF-1α mRNA and 
protein levels were also up-regulated. Analysis of NEU3-activated EGFR signaling revealed 
the activation of p70, which is known to promote HIF-1α transcription (Figure 3.8).  
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Figure 3.8: Scheme of EGFR signaling pathway activated by NEU3-induced GM3 
reduction. A) NEU3 removing sialic acid from gangliosides exposed on the outer membrane 
of adjacent cells B) mechanism of NEU3 activation of pro-survival signaling cascades, 
ultimately up-regulating HIF-1α 
 
These findings could also be useful for a better understanding of the NEU3 role in cancer, 
where sustained levels of HIF-1α are observed85 and are necessary for malignant 
progression under hypoxic conditions, which is the most suitable environment for tumor 
proliferation and growth. To further support the hypothesis of a key role played by 
ganglioside GM3 in activating the EGFR signaling cascade, we tried to mimic NEU3 
overexpression effects on reducing GM3 content by silencing GM3 synthase. Remarkably, 
GM3 synthase down-regulation, although only partial, caused a reduction in GM3 content in 
C2C12 cells which caused an increased cell survival upon subjection to hypoxia in 1% O2. 
Noticeably, although GM3 is approximately 97% of the total ganglioside content in i-NEU3 
cells, a significant reduction of gangliosides GD1a and GM2 could be observed upon NEU3 
silencing. Therefore, at this stage, we cannot exclude an involvement of these sphingolipids 
in NEU3 activity. Finally, whereas NEU3effects and mechanism of action seem to be 
clarified, little is known about how and whether the enzyme is physiologically up-regulated 
under hypoxia. Interestingly, it has been recently reported the binding of transcription factor 
SP1 and SP3 to the NEU3 promoter region86. These factors are ubiquitous transcription 
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factors (of the Sp/XKLF transcription factor family) that are involved in basal transcription 
and housekeeping gene expression, and they are known to be activated under hypoxic 
conditions87. Therefore, it is tempting to speculate that NEU3 response upon oxygen 
starvation might be regulated through SP1/SP3 activation. Interestingly, upon subjecting 
C2C12 cells to 1% O2, both SP1 and SP3 mRNA levels were found up-regulated, thus 
supporting their involvement in activating NEU3 gene transcription under hypoxic stress. 
Further investigations to test this hypothesis are ongoing in our laboratories. In a 
translational perspective, it would be very interesting to test whether NEU3 effects can be 
recognized also in other cells, in particular in those critically affected under hypoxic 
conditions in many pathologies, like cardiomyocytes and neural cells.  
As cardiac surgery offers the unique opportunity of in-vivo model of cardiac ischemia-
reperfusion, the second step of my PhD project was to investigate NEU3/HIF1α expression 
and activity in human cardiomyocytes from sample obtained during routine adult cardiac 
procedures. 
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CHAPTER 4: Acute Model of Cardiac Ischemia in Humans 
4.1 Introduction: Extracorporeal Perfusion 
Extracorporeal circulation (ECC) is a powerful technology that makes open-heart surgery, 
temporary circulatory or respiratory assistance, and long-term life support possible. 
Extracorporeal perfusion systems circulate blood and, depending on the application, 
ventilate, cool, rewarm or process blood. Because tubing transverses the skin barrier, all 
extracorporeal perfusion systems are designed for temporary application. Of necessity, 
blood comes into contact with the various biomaterials of the perfusion circuit, and 
unfortunately, this contact activates blood proteins and cells of the body’s defense system. 
Consequences of this activation cause most of the morbidity associated with the technology. 
Open-heart surgery required the development of a means to both pump and ventilate blood. 
The actual development of this technology has a long history spanning over 100 years and 
was enabled by the discovery of heparin in 1916 and protamine in 1937. Before John and 
Mary Gibbon developed the “heart-lung machine”, others had experimented with blood 
pumps and extracorporeal oxygenation of venous blood88. On May 6, 1953, Dr. Gibbon 
successfully closed an atrial septal defect in Cecelia Bovalak using cardiopulmonary bypass 
(CPB) provided by a machine made to the Gibbon design by the International Business 
Machines Corporation. The first successful series of patients with open-heart surgery using 
CPB was reported by Kirklin and DuShane in 1955. Since that time, multiple technical 
advances in equipment and practice have decreased the morbidity and mortality of 
extracorporeal circulation, reduced the need for massive blood transfusions and widened 
applications of the technology.  
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4.2 Conduction of Open Heart Surgery using ECC 
The heart-lung machine is the most “option-laden” model of extracorporeal perfusion 
systems. The basic components are one or more venous cannula, a venous reservoir, an 
oxygenator/heat exchanger, a pump, an arterial line filter and an arterial cannula. The 
machine is built from biocompatible materials that, by definition, are nontoxic, 
nonimmunogenic, nonallergic and nonmutagenic. 
Through one or more venous cannulas, deoxygenated blood drains by gravity into the 
extracorporeal circuit or pump-oxigenator system. The number of venous cannulas depends 
on the type of cardiac surgical procedure and, to some extent, on the surgeon’s preference. 
When one cannula is used, it is usually placed in the right atrium through the right atrial 
appendage. When two cannulas are used, they are placed in the superior and inferior venae 
cavae. Many surgeons for operations involving the aortic valve, the ascending aorta and 
coronary bypass procedures, use a single cavoatrial cannula. Two venous cannulas are 
necessary to work on the mitral valve, on the right atrium or ventricle.  
The arterial cannula is usually placed in the ascending aorta just proximal to the innominate 
artery, but it can be placed anywhere in the arterial system that is large enough to 
accommodate the necessary flow. Alternative cannulation sites include the femoral, iliac 
and axillary arteries.  
When ECC is started, an aortic cross-clamp is applied on the ascending aorta just 
proximally to the arterial line, in order to exclude the aortic root (and the coronary arteries) 
from the systemic circulation. This allowed the surgeon to operate on an empty, bloodless 
heart. On the other hand during aortic cross-clamp time, the heart is not perfused, so it is 
globally ischemic. To minimize the potential myocardial damage during this phase, several 
strategies to implement myocardial protection (cardioplegia, systemic cooling and topical 
cooling) have been developed during cardiac surgery history, and will be described in the 
next paragraph. 
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When surgery is finished, aortic cross-clamp is removed and the heart is allowed to 
reperfuse in an empty beating condition, in order to recover from the ischemic phase. 
Finally the heart is weaned from ECC and the chest is closed in a standard fashion. 
 
4.3 Cardioplegia and Myocardial Protection. 
The first open-heart surgery operation in 1952, used whole-body systemic hypothermia 
(∼28 °C) and brief (∼6 min) circulatory arrest. At that time, it was known that hypothermia 
was a protective mechanism that reduced organ oxygen requirement, particularly to the 
brain. The subsequent development of cardiopulmonary bypass prevented injury to the brain 
and other systemic organs, but the extended periods of global ischemia required to repair 
complex cardiac pathologies leading to increased mortality (often as high as 65%). A 
common phenomenon was the ‘stone-heart’, the result of maintained and irreversible 
contracture precipitated by ATP utilization during ischemia89. In an attempt to ameliorate 
this problem, Melrose et al.90 introduced the concept of ‘elective reversible cardiac arrest’ 
using an intracoronary artery infusion of a high concentration of potassium citrate (77 
mmol/L) added to blood. This ‘pharmacological arrest’ (now termed cardioplegia) induced a 
cell membrane depolarization, preventing conduction of the action potential and resulted in 
diastolic cardiac arrest. Reversibility of arrest was easily achieved by washout of the 
solution. However, this elevated potassium (hyperkalemia) citrate solution was subsequently 
found to induce focal myocardial necrosis and caused the death of many patients, resulting 
in the use of hyperkalemic solutions being abandoned for almost 20 years. Over this time 
period, surgeons used various techniques to protect the heart during ischemia, including 
continuous or intermittent normothermic perfusion, electrically induced ventricular 
fibrillation or topical (and profound) hypothermia; surgical results were generally good, but 
mortality rates were high (around 10–20%). Interestingly, the concept of pharmacological 
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arrest had been maintained throughout this period by surgeons in Germany, using 
cardioplegia developed by Bretschneider91 and now known as HTK solution. This solution 
was sodium-poor, calcium-free and contained procaine, a sodium channel blocker; it 
induced arrest by maintaining a polarized cell membrane and was used routinely with 
considerable success. Unfortunately, however, these advances were not widely known until 
much later due to original publications in the German literature. In the mid-1970s, to 
address the continued influence of ischemic injury during cardiac surgery, cardioplegic 
solutions were reintroduced into surgical practice. These solutions (developed in both the 
USA and in the UK) were based on a ‘extracellular-type’ ionic formulation and had 
moderately elevated potassium chloride concentrations92. Although earlier experimental 
studies had suggested that the focal necrosis seen in patients resulted from the high citrate 
concentrations, rather than the high potassium, this was not subsequently confirmed. At St. 
Thomas' Hospital in London, David Hearse (a biochemist) in collaboration with Mark 
Braimbridge (a cardiac surgeon) developed the St. Thomas' Hospital cardioplegic solutions. 
These solutions were characterized and optimized for each component (based on plasma 
concentrations) and had potassium concentrations of either 20 or 16 mmol/L (in St. Thomas' 
Hospital cardioplegic solution No. 1 or 2, respectively), elevated magnesium concentrations 
of 16 mmol/L, and normal ionized calcium concentrations. St. Thomas' Hospital 
cardioplegia was first used surgically in 197593; within 2–3 years, the use of crystalloid 
buffer-based cardioplegia became the predominant cardioprotective technique throughout 
the world, with the St. Thomas' solution being the most widely used crystalloid solution. 
Further development of cardioplegic solutions (from Buckberg's group)94 used blood as the 
vehicle for the arresting and protective agents. Blood cardioplegia is now the most 
commonly used form of hyperkalemic cardioplegia. Elective induction of ischemic cardiac 
arrest forms the cornerstone of myocardial protection for the majority of cardiac procedures 
(coronary artery bypass surgery and valve surgery) during cardiac operations. 
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Cardioprotection during this ischemia involves the application of a cardioplegic solution to 
induce rapid myocardial arrest and induce a flaccid diastolic state that allows the surgeon a 
relaxed non-beating operating field—the induction of ‘cardioplegia’, defined as ‘an elective, 
rapid and reversible paralysis of the heart during cardiac surgery’. The institution of 
cardioplegic arrest ensures that myocardial oxygen consumption (MVO2) is significantly 
reduced95, as is the ATP depletion characteristic of severe ischemia. Cardiac arrest can be 
induced in a number of ways, by targeting specific processes within excitation–contraction 
coupling (Figure 4.1). 
	
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure 4.1: The cellular targets for cardioplegic arrest and their influence on the action 
potential with examples of pharmacological agents. 
 
4.4 Development of acute human model of cardiac ischemia 
Cardiac surgery and ECC offer the unique opportunity to have a human model of cardiac 
ischemia/reperfusion. As in the in-vitro model we observed that NEU3 expression was 
significantly increase after ischemia, we developed the following model during cardiac 
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surgery procedure, in order to ascertain if the same variation of NEU3 expression levels 
occur also in human cardiomyocytes during ischemia. At single venous cannulation, a 
Satinsky Clamp was applied to the right appendage and the tip of the appendage was 
harvested, and divided into two samples (Figure 4.2).  
 
Figure 4.2: Right atrial appendage harvesting in the Operating Room during Cardiac 
Surgery Procedure. 
 
The first sample constituted the pre-ischemic control and was used to analyze gene and 
protein expression at baseline. Just before aortic cross-clamping remove (so at the end of the 
cardiac ischemic time) another sample was harvested from the tip of the right appendage, 
just near to the venous cannula, and was used to analyze gene and protein expression after 
ischemia. Aortic cross-clamp time as well as ECC time were collected for further analysis. 
The second appendage sample collected at the moment of venous cannulation was incubated 
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in hypoxic condition for the same time of aortic cross-clamp (ischemic time in vivo). This 
allowed us to rule out any confounding effect due to myocardial protection induced by 
cardioplegia and systemic cooling performed routinely during surgery. 
 
4.5 Materials and Methods 
Sample Collection 
Right atrial appendage biopsies were collected during cardiac surgery and ECC. At single 
venous cannulation, a Satinsky Clamp was applied to the right appendage and the tip of the 
appendage was harvested, and divided into two samples. The first sample was washed with 
PBS and freezed immediately in liquid nitrogen. It represented the pre-ischemic control, 
named “Pre”, and was used to analyze gene and protein expression at baseline. The second 
sample was incubated in PBS in hypoxic conditions (1% O2) for the same time of aortic 
cross-clamp and was names as “Hypoxia”.  
Just before aortic cross-clamping remove, at the end of the cardiac ischemic time, another 
sample of the right appendage was harvested, washed with PBS and freezed in liquid 
nitrogen. It was named “Post” and used to analyze gene and protein expression after 
ischemia. At the same time the sample incubated in hypoxic conditions was freezed in liquid 
nitrogen. Later on, the three samples collected were processed for mRNA isolation. 
 
mRNA isolation from cardiac tissue samples 
Regarding mRNA extraction, tissue samples were incubated with 1 ml of Trizol-LS reagent 
(Invitrogen, Carlsbad, CA, USA) and homogenized using the Tissue homogenizer Lyser® 
(Qiagen). Each sample was processed with 2 cycles of 10 minutes each at 25 
oscillations/second, kept in ice for 30 minutes and finally centrifuged at 12000 rcf for 5 
minutes at 4°C. After centrifugation, the supernatant of each sample was transferred in a 
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new tube and total mRNA was extracted from Trizol-LS following the manufacture’s 
protocol.		
 
mRNA purification and retro-transcription in cDNA 
To eliminate possible genomic DNA contaminations in the extracted mRNA, the samples 
were processed according to the "RNA Cleanup" protocol of RNeasy Mini Kit® 
(QUIAGEN), supplied by the company.  
mRNA quantity and purity were assessed by reading absorbance at 260 nm wavelength with 
a spectrophotometer Nanodrop (EuroClone). We considered suitable the samples with the 
following ratio: 
• A260/A280 greater than 1,9 that means no contamination by proteins 
• A260/A230 greater than 1,9 that means no contamination by carbs or phenol, which 
could affect retro-transcription efficacy. 
All the study samples satisfied both the aforementioned conditions. 
After isolation and purification, 1 µg of RNA was reverse-transcribed to cDNA using the 
iScript cDNA Synthesis Kit (Bio-Rad Laboratories) according to the manufacturer’s 
instruction. Briefly, for every sample the reaction mix was prepared as follow: 
 
 
 
 
 
 
The samples were reverse transcribed in a thermocycler using the following protocol:  
 5 minutes at 25°C; 30 minutes at 42°C; 5 minutes at 85°C and resting at 4°C 
Reaction Mix 4  µL 
Reverse transcriptase 1  µL 
RNA µL equivalent to 1 µg 
H2O µL to fill the volume 
Final Volume 20  µL 
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Gene expression analysis by Real Time PCR 
The quantitative expression of the genes of interest was assessed by Real Time PCR.  
Initially, the specific primers to evaluate the expression of the genes of interest have been 
designed with the “Primer3” software and then checked with the “Blastn” program to 
control their correct annealing with the identified target genes.  
For the analysis the following primers have been used: 
PRIMER MELTING T (°C) SEQUENCE 
S14 57 
Fw- GTGTGACTGGTGGGATGAAGG 
Rev- TTGATGTGTAGGGCGGTGATAC 
NEU3 57 
Fw- TGGTCATCCCTGCGTATACC 
Rev- TCACCTCTGCCACTTCACAT 
HIF-1α 57 
Fw- TTTTTCAAGCAGTAGGAATTGGA 
Rev- GTGATGTAGTAGCTGCATGATCG 
 
The single Real-Time PCR reactions were performed in a 96 well plate, mixing in a final 
volume of 20 µL the following reagents: 
• cDNA; 10 ng 
• Primers mix; 0,2 µM 
• 1X Power SYBR® Green PCR master mix (Thermo Fisher Scientific) containing: 
Sybr Green, Taq polymerase (0.6 U), MgCl2 (3 mM), Buffer (Tris/HCl 20 mM, KCl 
50 mM, pH 8.4), dNTPs (200 µM). 
The PCR reaction was performed under the following conditions: 
• Initial denaturation: 95°C for 2 minutes (1 cycle) 
• Denaturation: 95°C for 30 seconds 
• Annealing: 57°C for 30 seconds 
• Elongation, fluorescence detection: 72°C for 30 seconds 
• Final Elongation: 72°C for 2 minutes 
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The three steps (denaturation, annealing and elongation) were repeated for 40 cycles. At the 
end of the reaction, the Melting curve is obtained in order to rule out the presence of 
nonspecific products. Relative quantification of target genes was performed in triplicate and 
was calculated by the equation 2-ΔΔCt. 
 
Statistical analysis 
Data were expressed as a percentage for nominal variables and mean with standard 
deviations for continuous variables using GraphPad Prism 6 (GraphPad Software Inc, 
California, USA). Statistical differences were determined by Unpaired T-test (* p<0,05; ** 
p<0,01; *** p<0,001).  
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4.6 Results 
In this experimental model we enrolled 6 adult patients submitted to cardiac surgical 
procedure in the Cardiac Surgery Unit at IRCCS Policlinico San Donato. Inclusion criteria 
were age range between 18-80 years old, and the ability to sign an informed consent to the 
study protocol. The study was approved by the local ethical committee. All the patient 
clinical, surgical and follow-up data were collected and progressively inserted in an 
electronic database. 
Mean age was 72±8 years, and 4 patients were female. Regarding cardiac risk factor, 
hypertension, dyslipidemia and diabetes mellitus were present in 5 patients (83%), 4 
patients (67%) and 2 patients (33%) respectively. Three patients (50%) were operated of 
CABG, 2 patients (33%) underwent aortic valve replacement (AVR) and one patient (17%) 
was operated for ascending aortic aneurysm. All patients underwent surgical correction via 
median sternotomy with ECC. CABG was performed with left internal mammary on the left 
anterior descending coronary artery and great saphenous vein sequentially on the other 
branches. AVR was performed with bioprosthesis in both patients. Myocardial protection 
was achieved in every patients with antegrade crystalloid cardioplegia, topical cooling and 
systemic cooling (32 °C). Mean aortic cross-clamp time was 79±35 minutes. We observed 
no 30-days mortality. 
NEU3 and HIF-1α expression levels were not significantly different in samples harvested 
before and after aortic cross-clamping. The same lack of increase in NEU3 and HIF-1α 
expression was observed in the sample harvested before aortic clamping and incubated in 
hypoxic condition for the same time of in-vivo aortic cross-clamp. VEGF expression 
showed a trend towards an increase between pre-clamping and post-ischemia levels, even if 
this trend failed to reach statistical significance (Figure 4.3). 
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Figure 4.3: NEU3, HIF-1α and VEGF mRNA expression analysis by Real Time PCR of 
auricles samples harvested before aortic clamping (PRE), incubated in hypoxic conditions 
(Hypoxia) or harvested after ischemia (POST). 
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4.7 Discussion 
Several studies have found increased levels of HIF-1α messenger RNA (mRNA) in hypoxic 
cultured cells and in organs (the retina and lung) of animals exposed to short- or long-term 
hypoxia96. On the opposite very few studies reported data on HIF-1α expression in human 
model of cardiac ischemia. Lee and coworkers97 examine specimens of 37 human heart 
tissue affected by various degrees of ischemic insult and correlate the physiologic and 
pathological state of the heart with the temporal and spatial expression of HIF-1α and 
VEGF. In this study the authors detected increased steady-state levels of HIF-1α mRNA 
during the early period (the first 24 hours) after acute myocardial infarction or during acute 
myocardial ischemia. This accumulation of mRNA was limited to the region of affected 
myocardium. No HIF-1α transcripts were detectable by PCR analysis in specimens of non-
ischemic or non-infarcted tissue (Figure 4.4).  
 
Figure 4.4:  Results of Analysis of Ventricular-Biopsy Specimens by the Polymerase Chain 
Reaction. In specimens in the early-infarction group, the onset of infarction was less than 24 
hours before surgery; in those in the evolving-infarction group, the onset of infarction was 
24 to 120 hours before surgery; and in those in the ischemia group, the onset of ischemia 
was less than 48 hours before surgery. In each pair, 1 denotes the specimens taken from an 
area of normal ventricular tissue, and 2 the specimens taken from an area of ischemic or 
infarcted ventricular tissue. The lengths of the transcripts detected are shown on the right. 
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These results suggest that HIF-1α is an early molecular marker of myocardial ischemia or 
infarction. The production of this protein and its effects appear to be limited to the heart, 
since it was not detected in the peripheral blood of patients. 
Our results are partially consistent with these observations. Indeed, even a short ischemic 
time was sufficient to determine an increase in NEU3 and HIF-1α expression in cardiac 
sample harvested before venous cannulation and incubated in hypoxic conditions. On the 
contrary, in the complete in-vivo model, no significant activation of NEU3 and HIF-1α was 
evident in cardiac sample harvested before and after aortic cross-clamping. It is interesting 
to note that incubation time in hypoxic condition was set to be equivalent to in vivo 
ischemic time (aortic cross-clamping time). In our opinion there are several possible 
explanations to the lack of NEU3 and HIF-1α increased expression in the cardiac surgery 
model. First of all, despite in the in-vitro setting even a short ischemic period is enough to 
induce HIF-1α increased expression, it is possible that in the in-vivo setting the mean aortic 
cross-clamp time was too short to elucidate the same response.  
Secondly, and most important in our opinion, the technique of myocardial protection, 
especially cardioplegic arrest and hypothermia, by protecting the myocardium from the 
ischemic injury could have limited NEU3 and HIF-1α expression in our samples. Indeed, it 
is well known that hypothermia protects myocardium from oxidative injury during ischemic 
stress and reperfusion98. In the isolated, perfused rabbit heart model, Ning and colleagues99 
demonstrated that hypothermia at 30 °C preserves cardiac structural integrity and function 
for several hours after ischemic insult by the following mechanisms: 1) hypothermia 
preserves cardiac function by preventing rapid interstitial collagen fragmentation and loss of 
connective tissue framework due to direct reduction in matrix metalloproteinase 9 activity; 
2) the hearts exposed to hypothermia both before and during ischemia demonstrated full 
preservation of oxidative capacity, as indexed by MVO2 after 3 h of reperfusion. A 
hypothermia induced reduction in metabolic demand during ischemia is confirmed by 
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decreased lactate production; 3) hypothermia alters signaling for apoptosis as very little or 
no p53 expression was observed in 30°C-treated hearts. The similar lack of expression of 
p53 after hypothermic adaptation in the ischemia hearts suggests that modification of this 
pathway represents at least one mode for the hypothermic therapeutic effect. 4) 30 °C 
hypothermia was able to counteract the effects of severe hypoxia on HIF-1α expression by 
enhancing synthesis of HIF-1α protein through transcriptional regulation and by the 
inhibition of protein degradation. Indeed severe hypoxia without hypothermia determines a 
reduction of HIF-1α expression, while the application of hypothermia was able to maintain 
the value of HIF-1α protein to the level of non-ischemic control (Figure 4.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: RT-PCR results for mRNAs and proteins of hypoxia-inducible factor 1α (HIF-
1α). Hypothermia increases HIF-1α (P<0.05). Protein content is shown relative to β-actin 
for representative. 
 
Cardioplegia-induced cardiac arrest is a mainstay of cardiac surgery because attenuates 
myocardial injury and hastened recovery of cardiac function after aortic cross-clamping. 
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While it is well known that cardioplegia significantly affect myocardial metabolism, 
oxidative status and cytokines pattern100, no or little is described regarding cardioplegia 
effects on HIF-1α expression. Ryou and colleagues101 in a pig model of ECC and cardiac 
arrest analyzed the effects of conventional cardioplegia and pyruvate-enriched cardioplegia 
on myocardial expression of HIF-1α and erythropoietin. They showed that after 60 minutes 
of ischemia, myocardial HIF-1α mRNA content was similar between cardioplegia groups 
and non-ischemic controls. Furthermore, while standard cardioplegia didn’t affect 
myocardial HIF-1α protein content compared to control group, HIF-1α protein content was 
60-70% greater in the pyruvate cardioplegia group compared to the other two groups 
(Figure 4.6).  
 
Figure 4.6: HIF-1α mRNA expression and protein contents in left ventricular myocardium. 
Messenger RNA (A) and protein (B) were measured in myocardium sampled 4 h after CPB 
with control (hatched bars) or pyruvate-fortified (solid bars) cardioplegia, or at the 
corresponding sham time point (open bars). 
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Thus 60-min exposure to pyruvate-fortified cardioplegia during CPB augmented myocardial 
HIF-1α content 4 h later, without a significant increase in the corresponding mRNA. These 
results suggest that pyruvate augments HIF-1α content by suppressing degradation, not 
increasing expression of HIF-1α.  We previously described that Fe2+, O2-, and α-
ketoglutarate-dependent hydroxylation of two proline residues, catalyzed by prolyl 
hydroxylase, targets HIF-1α for proteosomal degradation. Pyruvate can interfere with this 
mechanism by competing with α-ketoglutarate for access to prolyl hydroxylase’s catalytic 
core102.  
In conclusion, the results of our in-vivo model of acute cardiac ischemia were partially 
conflicting. Indeed, as in the human cardiac samples cultured in the hypoxic incubator we 
were able to demonstrate an increase in HIF-1α and NEU3 gene expression, in cardiac 
samples from the same patients, submitted to aortic cross-clamping model of in-vivo 
ischemia we failed to demonstrate the same behavior of HIF-1α and NEU3 gene expression. 
This phenomenon was probably due, in our opinion, to the protective role of hypothermia 
and cardioplegia on human heart submitted to ischemic insult. Unfortunately, no cardiac 
surgery procedure is nowadays performed without these strategies of myocardial protection. 
We believe that our series of experiments could be useful to better elucidate the cardio-
protective effect of cardioplegia and hypothermia at cellular level, and it will be the object 
of future investigation. Unfortunately, at the moment, this is the major limitation of our 
model designed to evaluate HIF-1α and NEU3 expression in human in-vivo cardiac 
ischemia. 
To overcome these limitation, in the final part of my PhD program we sought to evaluate 
HIF-1α and NEU3 expression in a human in-vivo model of chronic cardiac hypoxia, 
studying patients affected by cyanotic cardiac defects submitted to surgical correction.   
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CHAPTER 5: Chronic Human Model of Cardiac Hypoxia 
5.1 Congenital Heart Defects 
Congenital heart disease (CHD) is the most common congenital anomaly, occurring in 
almost 1% of live births. Among birth defects, CHD is the leading cause of infant mortality. 
 
Etiology  
Environmental and genetic factors contribute to the development of CHD. Common 
environmental factors include maternal illness (eg, diabetes, rubella, systemic lupus 
erythematosus) or maternal intake of teratogenic agents (eg, lithium, isotretinoin, 
anticonvulsants). Paternal age may also be a risk factor. 
Certain numerical chromosomal abnormalities, such as trisomy 21, trisomy 18, trisomy 13, 
and monosomy X (Turner syndrome), are strongly associated with CHD. However, these 
abnormalities account for only about 5% of patients with CHD. Many other cases involve 
microscopic deletions on chromosomes or single-gene mutations. Often, the microscopic 
deletions and mutations cause congenital syndromes affecting multiple organs in addition to 
the heart. Examples include DiGeorge syndrome (microdeletion in 22q11.2) and Williams-
Beuren syndrome (microdeletion in 7p11.23). Single-gene defects that cause syndromes 
associated with CHD include mutations in fibrillin-1 (Marfan syndrome), TXB5 (Holt-Oram 
syndrome), and possibly PTPN11 (Noonan syndrome). Single-gene defects can also cause 
isolated (ie, nonsyndromic) congenital heart defects. 
The recurrence risk of CHD in a family varies depending on the cause. Risk is negligible in 
de novo mutations, 2 to 5% in nonsyndromic multifactorial CHD, and 50% when an 
autosomal dominant mutation is the cause. It is important to identify genetic factors because 
more patients with CHD are surviving into adulthood and potentially starting families. 
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Pathophysiology  
Congenital heart anomalies are classified as 
1. Cyanotic 
2. Acyanotic (left-to-right shunts or obstructive lesions) 
The physiologic consequences of congenital heart anomalies vary greatly, ranging from an 
asymptomatic heart murmur or abnormal pulses to severe cyanosis, congestive heart failure 
(HF), or circulatory collapse. 
Classification of Congenital Heart Anomalies*  
Cyanotic 
 
Tetralogy of Fallot 
Transposition of the great arteries 
Tricuspid atresia 
Pulmonary atresia 
Persistent truncus arteriosus 
Total anomalous pulmonary venous return 
Acyanotic 
Left-to-right 
shunt 
Ventricular septal defect 
Atrial septal defect 
Patent ductus arteriosus 
Atrioventricular septal defect 
Obstructive 
Pulmonic stenosis 
Aortic stenosis 
Aortic coarctation 
Hypoplastic left heart syndrome (often also manifests with cyanosis, 
which may be mild) 
*In decreasing order of frequency. 
 
Left-to-right shunts 
Oxygenated blood from the left heart (left atrium or left ventricle) or the aorta shunts to the 
right heart (right atrium or right ventricle) or the pulmonary artery through an opening or 
communication between the 2 sides. Immediately after birth, pulmonary vascular resistance 
is high and flow through this communication may be minimal or bidirectional. Within the 
first 24 to 48 h of life, however, the pulmonary vascular resistance progressively falls, at 
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which point blood will increasingly flow from left to right. The additional blood flow to the 
right side increases pulmonary blood flow and pulmonary artery pressure to a varying 
degree. The greater the increase, the more severe the symptoms; a small left-to-right shunt 
typically does not cause symptoms or signs. 
High-pressure shunts (those at the ventricular or great artery level) become apparent several 
days to a few weeks after birth; low-pressure shunts (atrial septal defects) become apparent 
considerably later. If untreated, elevated pulmonary blood flow and pulmonary artery 
pressure may lead to pulmonary vascular disease and eventually Eisenmenger syndrome. 
Large left-to-right shunts (eg, large ventricular septal defect [VSD], patent ductus arteriosus 
[PDA]) cause excess pulmonary blood flow and volume overload, which may lead to signs 
of HF and during infancy often result in failure to thrive. A large left-to-right shunt also 
decreases lung compliance, leading to frequent lower respiratory tract infections. 
 
Obstructive lesions 
Blood flow is obstructed, causing a pressure gradient across the obstruction. The resulting 
pressure overload proximal to the obstruction may cause ventricular hypertrophy and HF. 
The most obvious manifestation is a heart murmur, which results from turbulent flow 
through the obstructed (stenotic) point. Examples are congenital aortic stenosis, which 
accounts for 3 to 6% of congenital heart anomalies, and congenital pulmonary stenosis, 
which accounts for 8 to 12%. 
 
Cyanotic heart anomalies 
Varying amounts of deoxygenated venous blood are shunted to the left heart (right-to-left 
shunt), reducing systemic arterial O2 saturation. If deoxygenated hemoglobin is greater than 
5 g/dL, cyanosis results. Detection of cyanosis may be delayed in infants with dark 
pigmentation. Complications of persistent cyanosis include polycythemia, clubbing, 
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thromboembolism (including stroke), bleeding disorders, brain abscess, and hyperuricemia. 
Hypercyanotic spells can occur in infants with unrepaired tetralogy of Fallot. Depending on 
the anomaly, pulmonary blood flow may be increased (often resulting in HF in addition to 
cyanosis), normal, or reduced, resulting in cyanosis of variable severity. Heart murmurs are 
variably audible and are not specific. 
Heart failure 
Some congenital heart anomalies (eg, bicuspid aortic valve, mild aortic stenosis) do not 
significantly alter hemodynamics. Other anomalies cause pressure or volume overload, 
sometimes causing HF. HF occurs when cardiac output is insufficient to meet the body’s 
metabolic needs or when the heart cannot adequately handle venous return, causing 
pulmonary congestion (in left ventricular failure), edema primarily in dependent tissues and 
abdominal viscera (in right ventricular failure), or both. HF in infants and children has many 
causes other than congenital heart anomalies. 
Symptoms and Signs  
Manifestations of CHDs are varied but commonly include 
• Murmurs 
• Cyanosis 
• HF 
Other physical examination abnormalities may include circulatory shock, poor perfusion, 
abnormal 2nd heart sound (S 2 —single or widely split), systolic click, gallop, or irregular 
rhythm. Most left-to-right shunts and obstructive lesions cause systolic murmurs. Systolic 
murmurs and thrills are most prominent at the surface closest to their point of origin, 
making location diagnostically helpful. Increased flow across the pulmonary or aortic valve 
causes a midsystolic crescendo-decrescendo (ejection systolic) murmur. Regurgitant flow 
through an atrioventricular valve or flow across a VSD causes a holosystolic (pansystolic) 
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murmur, often obscuring heart sounds as its intensity increases. PDA causes a continuous 
murmur that is uninterrupted by the S 2 because blood flows through the ductus during 
systole and diastole. This murmur is 2-toned, having a different sound during systole (when 
driven by higher pressure) than during diastole. 
Central cyanosis is characterized by bluish discoloration of the lips and tongue and/or nail 
beds; it implies a low O 2 level (usually O 2 saturation < 90%). Perioral cyanosis and 
acrocyanosis (cyanosis of the hands and feet) without lip or nail bed cyanosis is caused by 
peripheral vasoconstriction rather than hypoxemia and is a common, normal finding in 
neonates. Older children with longstanding cyanosis often develop clubbing of the nail beds. 
In infants, symptoms or signs of HF include: 
• Tachycardia 
• Tachypnea 
• Dyspnea with feeding 
• Diaphoresis, especially with feeding 
• Restlessness, irritability 
• Hepatomegaly 
Dyspnea with feeding causes inadequate intake and poor growth, which may be worsened 
by increased metabolic demands in HF and frequent respiratory tract infections. In contrast 
to adults and older children, most infants do not have distended neck veins and dependent 
edema; however, they occasionally have edema in the periorbital area. Findings in older 
children with HF are similar to those in adult. 
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5.2 Material and Methods 
Tissue biopsies 
Right atrial appendage biopsies were obtained from the point of atrial cannulation at the 
beginning of extracorporeal circulation. The tissue specimens weighed about 100 mg and 
were collected in cold phosphate buffer solution (PBS) at pH 7.4, kept in ice and processed 
within minutes after collection. 
 
mRNA isolation from cardiac tissue samples 
Regarding mRNA extraction, tissue samples were rapidly retrieved from saline solution and 
incubated with 1 ml of Trizol-LS reagent (Invitrogen, Carlsbad, CA, USA). Biopsies were 
homogenized using the Tissue homogenizer Lyser® (Qiagen). Each sample was processed 
with 2 cycles of 10 minutes each at 25 oscillations/second, kept in ice for 30 minutes and 
finally centrifuged at 12000 rcf for 5 minutes at 4°C. After centrifugation, the supernatant of 
each sample was transferred in a new tube and total mRNA was extracted from Trizol-LS 
following the manufacture’s protocol.		
	
mRNA purification and retro-transcription in cDNA 
To eliminate possible genomic DNA contaminations in the extracted mRNA, the samples 
were processed according to the "RNA Cleanup" protocol of RNeasy Mini Kit® 
(QUIAGEN), supplied by the company. mRNA quantity and purity were assessed by 
reading absorbance at 260 nm wavelength with a spectrophotometer Nanodrop (EuroClone). 
We considered suitable the samples with the following ratio: 
• A260/A280 greater than 1,9 that means no contamination by proteins 
• A260/A230 greater than 1,9 that means no contamination by carbs or phenol, which 
could affect retro-transcription efficacy. 
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All the study samples satisfied both the aforementioned conditions. 
After isolation and purification, 1 µg of RNA was reverse-transcribed to cDNA using the 
iScript cDNA Synthesis Kit (Bio-Rad Laboratories) according to the manufacturer’s 
instruction. Briefly, for every sample the reaction mix was prepared as follow: 
 
 
 
 
 
 
The samples were reverse transcribed in a thermocycler using the following protocol:  
 5 minutes at 25°C; 30 minutes at 42°C; 5 minutes at 85°C and resting at 4°C 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
Reaction Mix 4  µL 
Reverse transcriptase 1  µL 
RNA µL equivalent to 1 µg 
H2O µL to fill the volume 
Final Volume 20  µL 
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Gene expression analysis by Real Time PCR 
The quantitative expression of the genes of interest was assessed by Real Time PCR.  
Initially, the specific primers to evaluate the expression of the genes of interest have been 
designed with the “Primer3” software and then checked with the “Blastn” program to 
control their correct annealing with the identified target genes.  
For the analysis the following primers have been used: 
PRIMER MELTING T (°C) SEQUENCE 
S14 57 
Fw- GTGTGACTGGTGGGATGAAGG 
Rev- TTGATGTGTAGGGCGGTGATAC 
NEU3 57 
Fw- TGGTCATCCCTGCGTATACC 
Rev- TCACCTCTGCCACTTCACAT 
SP1 57 
Fw- ATCATCACAAGCCAGTTCCA 
Rev- AGATGTCTGGTTTTGCTGGA 
SP3 57 
Fw- AGTGGGCAGTATGTTCTTCC 
Rev- TTTGAACCTGCTGACCATCT 
HIF-1α 57 
Fw- TTTTTCAAGCAGTAGGAATTGGA 
Rev- GTGATGTAGTAGCTGCATGATCG 
PHD2 57 
Fw- TGGGAGTTGCTGTTGAAGTCG 
Rev- CGTGCCGCCTGGAGAAAC 
GLUT1 57 
Fw- GGTTGTGCCATACTCATGACC 
Rev- CAGATAGGACATCCAGGGTAGC 
ALDO-A 57 
Fw- TTGCCAGTATGTGACCGAGAA 
Rev- GCCTTCCAGGTGATGTGGT 
GAPDH 57 
Fw- ACGGATTTGGTCGTATTGG 
Rev- CATGGGTGGAATCATATTGG 
PDK1 57 
Fw- ACCAGGACAGCCAATACAAG 
Rev- CCTCGGTCACTCATCTTCAC 
VEGF 57 
Fw- TGCCCGCTGCTGTCTAAT 
Rev- CCTCGGTCACTCATCTTCAC 
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The single Real-Time PCR reactions were performed in a 96 well plate, mixing in a final 
volume of 20 µL the following reagents: 
• cDNA; 10 ng 
• Primers mix; 0,2 µM 
• 1X Power SYBR® Green PCR master mix (Thermo Fisher Scientific) containing: 
Sybr Green, Taq polymerase (0.6 U), MgCl2 (3 mM), Buffer (Tris/HCl 20 mM, KCl 
50 mM, pH 8.4), dNTPs (200 µM). 
The PCR reaction was performed under the following conditions: 
• Initial denaturation: 95°C for 2 minutes (1 cycle) 
• Denaturation: 95°C for 30 seconds 
• Annealing: 57°C for 30 seconds 
• Elongation, fluorescence detection: 72°C for 30 seconds 
• Final Elongation: 72°C for 2 minutes 
The three steps (denaturation, annealing and elongation) were repeated for 40 cycles. At the 
end of the reaction, the Melting curve is obtained in order to rule out the presence of 
nonspecific products. Relative quantification of target genes was performed in triplicate and 
was calculated by the equation 2-ΔΔCt. 
 
Total proteins extraction from Trizol-LS samples 
Proteins from the phenol/chloroform layer obtained during the RNA extraction with Trizol-
LS, were extracted by the following protocol. Initially, 1,2 mL of cold methanol were added 
to the phenol/chloroform layer and vortexed. The samples were left for 10 minutes at 30°C 
and, after an incubation on ice for 5 minutes, were centrifuged at 12000 rcf for 10 minutes at 
4°C to sediment the proteins. The protein pellets were washed with 1 mL of cold methanol 
and centrifuged again at 12000 rcf for 10 minutes at 4°C. After centrifugation, the proteins 
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were resuspended in 0,5 mL of cold methanol and sonicated for 4 cycles of 5 seconds each 
in ice using burst sonication to generate a fine protein powder. Samples were then 
centrifuged for 1 minute at 2000 rcf and methanol was left to evaporate. Proteins were 
resuspended with 200 mL of a 0.25% Rapigest® solution in 50 mM ammonium bicarbonate 
and solubilized by alternate cycles of vortex and heat at 60°C. The obtained proteins were 
stored at -80 °C until used for Western Blot experiments. 
 
Membrane and citosol proteins separation 
To obtain membrane and cytosolic protein fractions, the fragments of auricles were 
incubated with PBS containing 1% protease and phosphatase inhibitors (Sigma-Aldrich) and 
homogenized using the Tissue homogenizer Lyser® (Qiagen). Each sample was processed 
with 4-5 cycles of 10 minutes each at 25 oscillations/second and the total tissue suspensions 
were lysed by sonication and then centrifuged at 800 rcf for 10 minutes to eliminate debris, 
unbroken cells and nuclear components. The obtained supernatants were subsequently 
centrifuged at 200000 rcf at 4°C for 20 min on a TL100 Ultracentrifuge (Beckman) to 
obtain soluble and particulate fractions. The particulate fraction contains the plasmatic 
membranes, the lysosomal membranes and the endoplasmic reticulum, while the 
supernatant contains the cytosol. Both the fractions were used for NEU3 expression analysis 
by Western Blot. 
 
Proteins expression analysis by Western Blot 
Proteins concentrations were measured by the Pierce™ BCA Protein Assay Kit (Thermo 
Fisher Scientific) following the manufacturer’s protocol. 30 µg of proteins were denatured 
by boiling for 5 minutes in sample buffer (62,5 mM Tris-HCl pH 6.8, 2% SDS (w/v), 10% 
glycerol (v/v), 5% 2-mercaptoethanol (w/v), 0,01% bromophenol blue (w/v)) and separated 
on a 10% polyacrylamide gel in denaturing conditions.  
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A discontinuous gel has been prepared composed by the stacking and the running gels.  
Stacking Gel Composition 
• Deionized water 
• Tris-HCl 1.5 M, pH 6.8 
• SDS 0.1% w/v 
• Acrylamide 4% 
• APS 10% w/v 
• TEMED 
10% Running Gel composition 
• Deionized water 
• Tris-HCl 1.5 M, pH 8.8 
• SDS 0.1% w/v 
• Acrylamide 10-12% 
• APS 10% w/v 
• TEMED 
 
Proteins were subsequently transferred onto nitrocellulose membranes by electroblotting 
using 100 Volt for 2 hours. Then, the membranes were incubated overnight in Tris-buffered 
saline (TBS: 10 mM Tris-HCl, pH 7.4, 150 mM NaCl), 0.1% (v/v) Tween 20 (TBS-Tween) 
containing 5% (w/v) dried milk or 5% (w/v) bovine serum albumin (BSA; Sigma) for the 
blocking buffer. Blots were incubated with a primary antibody in the appropriate blocking 
solution for 3 hours at room temperature.  
The primary antibodies used for the analysis were the following: 
PRIMARY ANTIBODY DILUTION MANUFACTURER 
Calnexin 1:10000 Epitomics ® 
NEU3 1:700 Abcam ® 
HIF-1α 1:1000 Novus Biologicals ® 
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PHD2 1:1000 Novus Biologicals® 
EGFR 1:1000 Cell Signaling ® 
p-EGFR 1:1000 Cell Signaling ® 
ERK 1:1000 Cell Signaling ® 
p-ERK 1:1000 Cell Signaling ® 
p38 MAPK 1:1000 Cell Signaling ® 
p-p38 MAPK 1:1000 Cell Signaling ® 
p70S6K 1:1000 Cell Signaling ® 
p-p70S6K 1:1000 Cell Signaling ® 
GAPDH 1:5000 Millipore ® 
 
The membranes were washed four times for 10 minutes with TBS-Tween and then 
incubated with the appropriate secondary antibody horseradish peroxidase (HRP) 
conjugated for 1 hour at room temperature. After four washes in TBS-Tween, the protein 
bands were detected using an ECL detection kit (Thermo Fisher Scientific) as described by 
the manufacturer. 
 
Statistical analysis 
Data were expressed as a percentage for nominal variables and mean with standard 
deviations for continuous variables using GraphPad Prism 6 (GraphPad Software Inc, 
California, USA). Statistical differences were determined by Unpaired T-test (* p<0,05; ** 
p<0,01; *** p<0,001).  Linear regression was performed on Delta Ct values of gene 
expression analysis of cyanotic patients to investigate trend and correlation using GraphPad 
Prism 6 (GraphPad Software Inc, California, USA). 
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5.3 Results 
Clinical Data and comparison among the two study Groups 
The study have enrolled 35 patients (17 cyanotic - Group A and 18 controls - Group B) 
submitted to elective cardiac surgery for cyanogen and non-cyanogen heart defects. 
Inclusion and exclusion criteria are herein reported. Enrollment began after the local Ethical 
Committee approved the study protocol. Every single patient included in the study was 
identified univocally by an alphanumeric code. All the patient clinical, surgical and follow-
up data were collected and progressively inserted in an electronic database.  
Inclusion Criteria: 
- Male or Female patients aged 2 months – 18 years 
- Patients affected by cyanogen or non-cyanogen heart defect 
- Patients listed for surgical correction of heart defect 
- Patients (or parents) must read and sign the informed consent to surgery. 
The two study groups included patients affected by different cardiac defects, as reported in 
Table 5.1 
Cyanotic Patients  Non-Cyanotic Patients 
Tetrology of Fallot (TOF) 6  Atrial Septal Defect (ASD) 9 
Doble-outlet Right Ventricle 
(DORV) 
3  Ventricular Septal Defect (VSD) 6 
Great Arteries Transposition 
(TGA) 
4  Supra-aortic Stenosis 1 
Truncus Arteriosus 2  AtrioVentricular Septal Defect 2 
Pulmonary Atresia + DIV + 
MAPCAS 
1    
Congenitally corrected TGA 1    
Total Number of pts 17  Total Number of pts 18 
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Regarding the preoperative characteristics, the two groups resulted not significantly 
different for what concern mean age (41±19 vs 49±30 months in Group A and B 
respectively), gender, renal function, serum glucose and platelet count. 
On the opposite mean arterial saturation resulted significantly lower in cyanogen patients 
(74% vs 99% in Group A and B respectively; p=0.01), while mean hemoglobin level (15±3 
mg/dl vs 12±1 mg/dl in Group A and B respectively) and mean hematocrit (45±9 vs 34±3% 
in Group A and B respectively) were significantly higher in cyanotic group. 
 
Evaluation of genic expression, protein expression and activity of NEU3 sialidases 
Right appendage samples in cyanotic and not cyanotic (Controls) patients were isolated and 
processed for mRNA and protein extraction, as described in the Materials and Methods 
section. This procedure allowed us to evaluate for the protocol genes mRNA levels, by 
means of Real Time PCR, and protein expression, by means of Western Blot.  
The analysis of NEU3 expression by Real-Time PCR was performed on 17 cyanotic 
samples and on 18 controls. The results showed that in cyanotic group, NEU3 mRNA level 
was 1.28 greater compared to controls (p< 0.05; Figure 5.1 A). Furthermore, as we 
demonstrated in the in-vitro model that the transcription factors SP1 and SP3 regulate NEU3 
gene transcription under hypoxic stress, we found that SP1/SP3 expression was significantly 
higher in cyanotic group (Figure 5.1 B and C). Finally, as NEU3 sialidase is linked to 
plasma membrane, we evaluated the differences in NEU3 expression in cellular membranes 
or in cytosol among the two study groups. As expected, NEU3 membrane expression was 
significantly higher in cyanotic group, while no differences between the two groups were 
observed regarding cytosol NEU3 expression (Figure 5.1 D and E) 
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Figure 5.1: A) NEU3 mRNA expression in both study groups. B-C) SP1 and SP3 mRNA 
expression in both study groups. D-E) NEU3 mRNA expression in membranes and cytosol. 
Cyanotic are depicted as gray bar, controls are the white bar. All data assessed by means of 
Real-Time PCR. *, **, *** all p level < 0.05 
 
 
Evaluation of activation of epidermal growth factor receptor (EGFR) and of its 
downstream signaling pathways 
As assessed in our in-vitro model, NEU3 activity results in a direct activation of EGFR and 
its anti-apoptotic and proliferative downstream pathways. In both the study groups, we 
studied both EGFR expression and its activation by phosphorylation. In cyanotic group both 
EGFR expression (6.34 folds higher as compared to controls; p=.05) and EGFR activation 
(4.26 folds higher than controls; p=.05) resulted significantly greater compared to controls 
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(Figure 5.2-A). We further evaluated the expression of the proteins involved in the EGFR 
downstream signaling pathways. The analysis by Western Blotting showed an activation of 
ERK and AKT pathways in cyanotic compared to controls. Particularly, cyanotic patients 
showed both increased levels of proteins involved in cellular proliferation ERK and p38 
MAPK (8 and 3.5 folds greater than controls, respectively) and an increase in key proteins 
for cellular survival like p70S6K (2.18 folds greater than controls). The same results were 
observed in the phosphorylated isoform of the same proteins, which resulted significantly 
more expressed in cyanotic compared to controls (Figure 5.2 B-D) 
 
Evaluation of gene and protein expression of hypoxia inducible factor (HIF) and of its 
transcriptional targets 
We further evaluated Hypoxia Inducible Factor 1α (HIF-1α) expression by Real Time PCR 
and Western Blot in cyanotic and in control groups. We observed that in patients with 
chronic hypoxia there is an increase of HIF-1α gene expression of 1.3 folds as compared to 
controls (p=.05). This fact is also confirmed by a moderate increase in protein expression 
(Figure 5.3). 
Furthermore we evaluated the expression of some HIF target genes in order to verify the 
activation of the signaling pathway in response to the hypoxia. Particularly, the gene 
expression of the Vascular Endothelial Growth Factor (VEGF), a key angiogenetic factor, as 
assessed by Real Time PCR resulted 1.16 greater in cyanotic compared to controls, even if 
the expression of the corresponding protein, as assessed by Western Blot, was not 
significantly different among the two study groups (Figure 5.4) 
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Figure 5.2: Levels of protein expression and of their phosphorylated form in Western Blot 
of A) EGFR, p-EGFR; B) ERK, p-ERK; C) p38,p-p38; and D) p70S6K and p- p70S6K. 
Cyanotic are depicted as gray bar, controls are the white bar. 
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Figure 5.3: Gene and protein expression levels of HIF-1α assessed by Real Time PCR and 
Western Blot. Cyanotic are depicted as gray bar, controls are the white bar 
 
 
 
Figure 5.4: Gene expression levels of VEGF assessed by Real Time PCR. Cyanotic are 
depicted as gray bar, controls are the white bar 
 
We further examined some genes, downstream HIF-1α signaling pathway, involved in the 
regulation of glycolytic metabolism. Data showed that the gene expression of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), of the glucose transporter GLUT1 
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and of the aldolase was 1.127, 2.22 and 1.59 greater in cyanotic as compared to controls, 
respectively (p=.05) (Figure 5.5 A,B,D). Furthermore, we found a metabolic switch toward 
a glycolysis in cardiac cells of cyanotic patients as compared to controls. This was 
confirmed by a 1.26-fold increase in gene expression of pyruvate dehydrogenase kinase 
(PDK1) in cyanotic compared to controls (Figure 5.5 C). PDK1inhibits the transformation 
from pyruvate to Acetil-CoA, thus inhibiting mitochondrial function, oxygen consumption 
and energy production, which can only be obtained from the glycolytic pathway.  
 
Figure 5.5: Gene expression levels of GLUT1, Aldolase, PDK1 and GAPDH, assesses by 
Real Time PCR. Cyanotic are depicted as gray bar, controls are the white bar 
 
As a target of HIF-1α we further evaluated the prolyl hydroxylases PHD2 because, in 
hypoxic condition, its expression is regulated by HIF-1α itself through a mechanism of 
negative feedback. As shown in Figure 5.6, the level of mRNA was not significantly 
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different between the two groups, while the protein level as assessed by Western Blot was 
2.5 greater in cyanotic patients compared to controls. 
 
Figure 5.6: Gene and Protein expression levels of PHD2 assessed by Real Time PCR and 
Western Blot. Cyanotic are depicted as gray bar, controls are the white bar. *, p=<0.05 
Finally we observed a strong correlation between NEU3 and HIF-1α expression levels in 
both groups, which was significantly stronger and steeper among the cyanotic group 
(R2=0.49; p= 0.02; Figure 5.7) 
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Figure 5.7: Correlation between sialidase NEU3 and HIF-1α mRNA expression. Cyanotic 
are black circles, controls are white circles.  
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5.4 Discussion 
The present research project was developed analyzing samples of human cardiac right 
appendage, harvested during surgery on patients with low arterial saturation (SaO2<90% - 
Cyanotic Group) compared to patients with normal saturation (Controls). The results 
showed a significant increase in NEU3 expression and activity in patients affected by 
chronic hypoxia. Furthermore a significant increase of EGFR was observed, supporting the 
hypothesis that this signaling pathway is upregulated by the sialidase NEU3. Indeed we 
observed an increase in expression of genes downstream of EGFR, both related to cellular 
proliferation (ERK and p38) and to apoptosis resistance (AKT and p70S6K). Finally we 
observed a significant activation of HIF-1α and of its downstream genes.  
To our knowledge, there are no published studies on NEU3 sialidase expression in human 
in-vivo model of chronic hypoxia. Furthermore, there are very few papers in literature 
reporting on HIF-1α activation in the same model. Quing and colleagues103 reported data on 
HIF-1α and VEGF expression in cardiac samples from 7 cyanotic and 7 control patients 
submitted to surgical correction of congenital cardiac defects. The authors demonstrated that 
HIF-1α expression and activity are significantly elevated in the myocardium of infants with 
cyanotic congenital heart disease compared to those with acyanotic CHD, and that this 
response directly correlates with the degree of hypoxemia (Figure 5.8). 
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Figure 5.8:  A) Levels of hypoxia-inducible factor-1α (HIF-1α) were measured by Western 
blotting in the right ventricular myocardium of infants with congenital cardiac defects using 
an antibody against human HIF-1α. β-actin levels served as loading controls. (+): samples 
derived from infants with cyanosis (solid bar, n=7); [–] samples derived from patients 
without cyanosis (open bar, n=7). Results are expressed as the mean value±SEM. * p<0.05 
between groups. B) HIF-1α protein levels correlate with the degree of hypoxemia.  The ratio 
HIF-1α/ β-actin was related to the preoperative transcutaneous arterial oxygen saturation 
(SaO2) (n=14). Spearman correlation coefficient: –0.74 (p<0.005). 
 
 
Furthermore they showed increased intra-myocardial levels of VEGF in cyanotic compared 
to acyanotic patients, indicating that reduced oxygen availability is the critical element 
promoting VEGF expression in infants with congenital heart disease. These findings are 
supported by previous studies showing higher serum levels of VEGF in children with 
cyanotic cardiac defects as compared to others with acyanotic defects104. The importance of 
myocardial upregulation of VEGF is highlighted by an elegant study by Giordano et al.105 
where cardiomyocyte-specific deletion of VEGF-A resulted in fewer coronary microvessels, 
thinned ventricular walls, and depressed basal contractile function, but had also systemic 
consequences confirming the important role of cardiomyocytes in VEGF secretion. Since 
VEGF is the major factor promoting angiogenesis and neovascularization and can contribute 
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to myocardial remodeling, enhanced levels of VEGF may contribute to the abnormal vessel 
formation (i.e., aortopulmonary collateral arteries) and myocardial remodeling in infants 
with cyanotic congenital heart defects. 
As we demonstrated that NEU3 activity results in a direct activation of EGFR and its anti-
apoptotic and proliferative downstream pathways, in the present study cyanotic patients 
showed both increased levels of proteins involved in cellular proliferation ERK and p38 
MAPK as an increase in key proteins for cellular survival like p70S6K and AKT. These 
results are consistent with those reported by Kietzmann and coworkers106, who 
demonstrated that activation of p38 MAP kinase was significantly enhanced in the 
myocardium of infants with cyanotic congenital heart disease compared to those with 
acyanotic defects. They showed that an over-expression of the upstream kinases of p38 
MAP kinase, MKK3 and MKK6, but not of ERK1/2, induced HIF-1α protein levels and 
activated the HIF pathway in hypoxia, suggesting that activation of p38 MAP kinase may 
contribute to enhanced levels of HIF-1α in infants with cyanotic congenital heart disease. 
It has been shown  in the literature that HIF-1α reaches its maximum expression level after 
four hours of hypoxia, while during more extensive hypoxic periods, and ultimately in 
chronic hypoxia, HIF-1α levels progressively decrease107. Indeed, through a negative 
feedback mechanism, HIF-1α stimulates the transcription and the expression of prolyl 
hydroxylases (PHDs), aiming to limit an excessive concentration of HIF-1α itself. This 
reduction of HIF-1α level prepares the cell to better resist to an eventual re-oxygenation, 
thus limiting the ischemia/reperfusion injury. This is consistent with the data emerging from 
the present study, which showed a significant increase in PHD2 levels in hypoxic patients 
compared to controls. This process of autoregulation of HIF-1α expression by means of 
activation of its degradative proteins has been highlighted in an elegant study by Reddy and 
colleagues108, and is extremely important to understand the mechanisms of right ventricular 
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response to chronic hypoxia in congenital heart defects. The authors reported on 23 patients 
affected exclusively by Tetralogy of Fallot (TOF) and showed that the right ventricle in 
TOF failed to mount an adaptive response to hypoxia. Increasing hypoxia was associated 
with downregulation instead of upregulation of angiogenic and metabolic genes. 
Furthermore, they showed an upregulation of procollagen type 1 α1 gene expression, which 
is one of the major forms of collagen in endomyocardial tissue. Endomyocardial fibrosis has 
been described in TOF after late repair and it has been postulated that this may cause a 
restrictive RV physiology, which adversely impacts the early postoperative course. 
However, it must be note that TOF is a pathology in which sub-pulmonary stenosis 
determines an important RV hypertrophy, that consequently triggers endomyocardial 
fibrosis resulting in RV impaired response to cyanotic defect.  
Another important aspect of cellular adaptation to hypoxia is the metabolic switch between 
oxidative and glycolytic metabolism, the so-called “Pasteur effect”. The Pasteur effect, 
which describes the increased conversion of glucose to lactate in hypoxic cells, has been 
considered a critical cellular metabolic adaptation to hypoxia for over a century. Under 
normal oxygen tensions, cells catabolize glucose to pyruvate via glycolytic enzymes. 
Pyruvate is then taken up by the mitochondria for further catabolism through the 
tricarboxylic acid (TCA) or Krebs cycle, which transfers electrons to the respiratory chain. 
Electron transport through this chain results in ATP production and terminates in the 
donation of electrons to oxygen. In low oxygen tension, in which there is a paucity of 
oxygen as an electron acceptor, hypoxic cells are surmised to undergo anaerobic glycolysis 
as a default mode. Increased glycolytic flux requires transcriptional activation of genes 
encoding glucose transporters and glycolytic enzymes that is mediated by HIF-1α109. 
Hypoxic activation of HIF-1α promotes ATP production through increased anaerobic 
glycolysis, which partially compensates for hypoxic cellular energy demands. According to 
these observation, in the present study we found that the glycolytic enzymes Glucose 
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transporter Glut1, the Aldolase and the GAPDH were significantly enhanced in the cyanotic 
group which in turn demonstrates that the myocardium of patients affected by cyanogen 
cardiac defects is metabolic adapted to chronic hypoxia.   
Increased ATP production via the glycolytic pathway, however, may not be sufficient for 
hypoxic adaptation since hypoxia paradoxically causes oxidative stress from uncontrolled 
mitochondrial generation of reactive oxygen species (ROS) that may pose a barrier for cell 
survival. The hypoxia inducible pyruvate dehydrogenase kinase 1 (PDK1) is critical for the 
attenuation of mitochondrial ROS production, maintenance of ATP levels, and adaptation to 
hypoxia. PDK1 phosphorylates the pyruvate dehydrogenase (PDH) E1α subunit and 
inactivates the PDH enzyme complex that converts pyruvate to acetyl-coenzyme A, thereby 
inhibiting pyruvate metabolism via the Krebs cycle. Because the TCA cycle is coupled to 
electron transport, regulation of the PDH complex by PDK1 is critical for the attenuation of 
mitochondrial respiration and ROS production. Recently Kim and coworkers110 
demonstrated that the gene encoding PDK1 is a direct target of HIF-1α, and that 
overexpression of PDK1 in hypoxic HIF-1α knock-out cells was able to protect the cell 
itself against apoptosis, limiting the production of ROS. According to these authors HIF-1α 
plays three critical roles in the hypoxia-induced metabolic switch from oxidative to 
glycolytic metabolism. HIF-1α induces expression of: (1) upstream glucose transporters and 
glycolytic enzymes to increase flux from glucose to pyruvate; (2) PDK1 to block the 
conversion of pyruvate to acetyl CoA; and (3) lactate dehydrogenase A to convert pyruvate 
to lactate (Figure 5.9).  
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Figure 5.9: Coordinate regulation of hypoxia-induced metabolic switches by HIF-1α. In 
hypoxic cells, HIF-1α stimulates increased glycolytic flux to pyruvate (1) and its reduction 
to lactate (2). In addition, HIF-1α-induced PDK1 activity inhibits PDH (3), resulting in 
decreased flux through the TCA cycle. HIF-1α mediates these effects through 
transcriptional activation of genes encoding glucose transporters and glycolytic enzymes 
(1), lactate dehydrogenase A (2), and PDK1 (3). 
 
 
Our results are consistent with these observations, as we found that PDK1 expression is 
significantly greater in cyanotic patients compared to controls. Furthermore, the PDK1 
enzyme is activated by the protein PI3K which is downstream the EGFR pathway. As we 
demonstrated that NEU3-induced EGFR expression is enhanced in cyanotic group, it is 
reasonable to conclude that in chronic ischemic myocardium NEU3 sialidase contributes to 
cellular metabolic adaptation  
In conclusion, the present study showed that NEU-3 sialidase is activated in human cardiac 
cells that are chronically hypoxic. These results support the hypothesis of a physiological 
role of NEU-3 in mediating cellular response to hypoxic stress. It’s interesting to underline 
that NEU-3 activation is mediated by ganglioside GM3 on cellular membrane. Indeed, an 
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increase in NEU-3 level determines a reduction of GM3, which is a well know inhibitor of 
EGF receptor. Thus NEU-3 activation ultimately lead to EGF receptor activation. On these 
premises, to mimic the effects of NEU-3 activation, it could be possible to inhibit GM3 
synthesis, in example by the selective inhibition of the sialyl-transferase involved in the last 
passage of its synthesis. In this direction, our laboratory is performing some experiments 
with small chemical molecules, designed for blocking selectively the GM3 synthesis with 
the aim of activating the endogenous response to hypoxic stress. 
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CHAPTER 6: Conclusions 
The hypoxic condition determines several functional consequences that ultimately lead to 
cellular death and irreversible damage to cardiac myocytes. Under hypoxic condition, cells 
activate several protective pathways; among them, HIF-1α plays a key role in controlling 
cellular response to hypoxia at molecular level. However, HIF-1α regulatory mechanisms 
are extremely complex. On these premises the present work was based on the hypothesis 
that NEU3 sialidase, a glycolytic enzyme ubiquitously expressed over the plasmatic 
membrane, can have a regulatory activity on HIF-1α expression in hypoxic/ischemic cardiac 
myocytes.  
The experiments performed in this in-vitro model allowed us to draw the following 
conclusions: 
1) Endogenous NEU3 sialidase expression and activity are up-regulated in murine 
skeletal muscle cells (C2C12) upon oxygen starvation, leading to a signaling cascade 
resulting in the activation of HIF-1α.  
2) Moreover, induced overexpression of NEU3 significantly increases HIF-1α 
expression and cell resistance to hypoxic stress, whereas NEU3 silencing causes the 
opposite effects and renders myoblasts more susceptible to apoptosis. 
3) The hypoxia-driven activation of NEU3 sialidase can activate the EGFR pro-
survival signaling pathway by controlling the content of ganglioside GM3. 
Furthermore, we demonstrated that NEU3 overexpression causes a reduction of 
ganglioside GM3, which is known to block EGFR autophosphorylation.  
Then resulted were extended from skeletal muscle to cardiac myocytes, particularly aiming 
to ascertain the role of NEU3 in activating the human cardiomyocyte response to hypoxia. 
Particularly, we evaluated if NEU3 activation occurred in human cardiomyocytes using two 
different models:  
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- A model of acute cardiac ischemia achieved during aortic cross-clamp time and 
extracorporeal circulation in adult patient submitted to cardiac surgical procedures. 
- A model of chronic hypoxia in neonates and young patients operated for cyanogen 
congenital cardiac defects. 
In the acute model of cardiac ischemia, we harvested a sample of right atrial appendage just 
before and after aortic cross-clamping, during routine adult cardiac surgery procedure. After 
initiating the extracorporeal circulation, the application of aortic clamp excludes the aortic 
root (and the coronary arteries) from systemic perfusion. This step is mandatory for cardiac 
surgeons in order to operate on a bloodless, empty field, but it’s also a unique opportunity to 
have an in-vivo model of human cardiac ischemia.  
However, no significant activation of NEU3 and HIF-1α was evident in cardiac sample 
harvested before and after aortic cross-clamping. In our opinion there are several possible 
explanations for the lack of NEU3 and HIF-1α increased expression in the cardiac surgery 
model. First of all, it is possible that in the in-vivo setting the mean aortic cross-clamp time 
was too short (mean time = 79 minutes) to elucidate the same response that we observed in 
the in vitro model, where the cells were incubated under hypoxic conditions for at least 12 
hours. This fact suggests the hypothesis that NEU3 activation in ischemic condition is a 
relatively slow response and that its transcriptional pathways ultimately leading to HIF-1α 
activation requires a sufficient time of hypoxia to induce cell adaptive mechanisms.    
Secondly, and most important in our opinion, the technique of myocardial protection, 
especially cardioplegic arrest and hypothermia, by protecting the myocardium from the 
ischemic injury could have limited NEU3 and HIF-1α expression in our samples. 
Unfortunately, no cardiac surgery procedure is nowadays performed without these strategies 
of myocardial protection. We believe that our series of experiments could be useful to better 
elucidate the cardio-protective effect of cardioplegia and hypothermia at cellular level, and 
it will be the object of future investigation. Unfortunately, at the moment, this is the major 
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limitation of our model designed to evaluate HIF-1α and NEU3 expression in human in-
vivo cardiac ischemia. 
To overcome these limitation, in the final part of my PhD program we evaluated HIF-1α and 
NEU3 expression in a human in-vivo model of chronic cardiac hypoxia, studying patients 
affected by cyanotic cardiac defects submitted to surgical correction. In this model we 
harvested the tip of the right appendage at the moment of venous cannulation (with the same 
technique we validated in the acute model) and we compared the levels of NEU3, HIF-1α 
and their downstream pathways expression to those of patients operated for non-cyanogen 
cardiac defects (controls). Patients with cyanogen cardiac defects live since their birth with 
a mean arterial oxygen saturation of nearly 70%, compared to patients affected by non-
cyanogen defects who have normal saturation levels. So cyanogen patients are exposed to 
chronic hypoxia till the moment of surgical correction, which occurs at least some months 
after the birth, depending on the different pathologies. 
In this model of chronic hypoxia we observed a significant increase in NEU3 expression 
and activity in cyanotic patients. Furthermore a significant increase of EGFR was observed, 
supporting the hypothesis that this signaling pathway is upregulated by the sialidase NEU3. 
Indeed we observed an increase in expression of genes downstream of EGFR, both related 
to cellular proliferation (ERK and p38) and to apoptosis resistance (AKT and p70S6K). 
Finally we observed a significant activation of HIF-1α and of its downstream genes.  
Another important aspect of cellular adaptation to hypoxia is the metabolic switch between 
oxidative and glycolytic metabolism, the so-called “Pasteur effect”. Increased glycolytic 
flux requires transcriptional activation of genes encoding glucose transporters and glycolytic 
enzymes that is mediated by HIF-1α. Hypoxic activation of HIF-1α promotes ATP 
production through increased anaerobic glycolysis, which partially compensates for hypoxic 
cellular energy demands. According to these observation, in the present study we found that 
the glycolytic enzymes Glucose transporter Glut1, the Aldolase and the GAPDH were 
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significantly enhanced in the cyanotic group which in turn demonstrates that the 
myocardium of patients affected by cyanogen cardiac defects is metabolic adapted to 
chronic hypoxia.   
In conclusion, the results of this PhD project support the hypothesis of a physiological role 
of NEU3 in mediating cellular response to hypoxic stress. It is interesting to underline that 
NEU3 activation is mediated by ganglioside GM3 on cellular membrane. Indeed, an 
increase in NEU3 level determines a reduction of GM3, which is a well know inhibitor of 
EGF receptor. Thus NEU3 activation ultimately lead to EGF receptor activation. On these 
premises, to mimic the effects of NEU3 activation, it could be possible to inhibit GM3 
synthesis, in example by the selective inhibition of the sialyltransferase involved in the last 
passage of its synthesis. In this direction, our laboratory is performing some experiments 
with small chemical molecules, designed for blocking selectively the GM3 synthesis with 
the aim of activating the endogenous response to hypoxic stress. 
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